Selegiline

Overview

Selegiline, also known as L-deprenyl and sold under the brand names Eldepryl, Zelapar, and Emsam among others, is a medication which is used in the treatment of Parkinson's disease and major depressive disorder. It has also been studied and used off-label for a variety of other indications, but has not been formally approved for any other use. The medication, in the form licensed for depression, has modest effectiveness for this condition that is similar to that of other antidepressants. Selegiline is provided as a swallowed tablet or capsule or an orally disintegrating tablet (ODT) for Parkinson's disease and as a patch applied to skin for depression.[1–11] WP

Side effects of selegiline occurring more often than with placebo include insomnia, dry mouth, dizziness, anxiety, abnormal dreams, and application site reactions (with the patch form), among others. At high doses, selegiline has the potential for dangerous food and drug interactions, such as tyramine-related hypertensive crisis (the so-called "cheese reaction") and risk of serotonin syndrome. However, doses within the approved clinical range appear to have little to no risk of these interactions. In addition, the ODT and transdermal patch forms of selegiline have reduced risks of such interactions compared to the conventional oral form. Selegiline has no known misuse potential or dependence liability and is not a controlled substance except in Japan.[1][3][6][7][9–18] WP

Selegiline acts as a monoamine oxidase inhibitor (MAOI) and thereby increases levels of monoamine neurotransmitters in the brain. At typical clinical doses used for Parkinson's disease, selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B), increasing brain levels of dopamine. At higher doses, it loses its specificity for MAO-B and also inhibits monoamine oxidase A (MAO-A), which increases serotonin and norepinephrine levels in the brain as well. In addition to its MAOI activity, selegiline is a catecholaminergic activity enhancer (CAE) and enhances the impulse-mediated release of norepinephrine and dopamine in the brain. This action may be mediated by TAAR1 agonism. After administration, selegiline partially metabolizes into levomethamphetamine and levoamphetamine, which act as norepinephrine releasing agents (NRAs) and may contribute to its therapeutic and adverse effects as well. The levels of these metabolites are much lower with the ODT and transdermal patch forms of selegiline. Chemically, selegiline is a substituted phenethylamine and amphetamine, a derivative of methamphetamine, and the purified levorotatory enantiomer of deprenyl (the racemic mixture of selegiline and D-deprenyl).[5][9][10][11][13][16][19–31] WP

Deprenyl was discovered and studied as an antidepressant in the early 1960s by Zoltan Ecseri, József Knoll, and other colleagues at Chinoin Pharmaceutical Company in Hungary. Subsequently, selegiline was purified from deprenyl and was studied and developed itself. Selegiline was first introduced for medical use, to treat Parkinson's disease, in Hungary in 1977. It was subsequently approved in the United Kingdom in 1982 and in the United States in 1989. The ODT was approved for Parkinson's disease in the United States in 2006 and in the European Union in 2010, while the patch was introduced for depression in the United States in 2006. Selegiline was the first selective MAO-B inhibitor to be discovered and marketed. In addition to its medical use, there has been interest in selegiline as a potential anti-aging drug and nootropic. However, effects of this sort are controversial and uncertain. Generic versions of selegiline are available in the case of the conventional oral form, but not in the case of the ODT or transdermal patch forms.[5][31–45] WP

Uses, dosage and effects

Parkinson's disease

In its oral and ODT forms, selegiline is used to treat symptoms of Parkinson's disease (PD). It is most often used as an adjunct to medications such as levodopa (L-DOPA), although it has been used off-label as a monotherapy. The rationale for adding selegiline to levodopa is to decrease the required dose of levodopa and thus reduce the motor complications of levodopa therapy. Selegiline delays the point when levodopa treatment becomes necessary from about 11 months to about 18 months after diagnosis. There is some evidence that selegiline acts as a neuroprotective and reduces the rate of disease progression, though this is disputed. In addition to parkinsonism, selegiline can improve symptoms of depression in people with Parkinson's disease. There is evidence that selegiline may be more effective than rasagiline in the treatment of Parkinson's disease. This may be due to pharmacological differences between the drugs, such as the catecholaminergic activity enhancer (CAE) actions of selegiline which rasagiline lacks.[1][2][5][22][25][46–52] WP

Depression

Selegiline is used as an antidepressant in the treatment of major depressive disorder (MDD). Both the oral selegiline and transdermal selegiline patch formulations are used in the treatment of depression. However, oral selegiline is not approved for depression and is used off-label for this indication, while the transdermal patch is specifically licensed for treatment of depression. Both standard clinical doses of oral selegiline (up to 10 mg/day) and higher doses of oral selegiline (e.g., 30 to 60 mg/day) have been used to treat depression, with the lower doses selectively inhibiting MAO-B and the higher doses producing dual inhibition of both MAO-A and MAO-B. Unlike oral selegiline, transdermal selegiline bypasses first-pass metabolism, thereby avoiding inhibition of gastrointestinal and hepatic MAO-A and minimizing the risk of food and drug interactions, whilst still allowing for selegiline to reach the brain and inhibit MAO-B.[1][3][6][11] WP

A 2023 systematic review and meta-analysis evaluated the effectiveness and safety of selegiline in the treatment of psychiatric disorders including depression. It included both randomized and non-randomized published clinical studies. The meta-analysis found that selegiline was more effective than placebo in terms of reduction in depressive symptoms (SMD (standardized mean difference) = −0.96, k = 10, n = 1,308), response rates for depression improvement (RR (risk ratio) = 1.61, k = 9, n = 1,238), and response rates for improvement of depression with atypical features (RR (risk ratio) = 2.23, k = 3, n = 136). Oral selegiline was significantly more effective than the selegiline patch in terms of depressive symptom improvement (SMD (standardized mean difference) = −1.49, k = 6, n = 282 vs. SMD (standardized mean difference) = −0.27, k = 4, n = 1,026, respectively; p = 0.03). However, this was largely due to older and less methodologically rigorous trials that were at high risk for bias. Oral selegiline studies also often employed much higher doses than usual, for instance 20 to 60 mg/day. The quality of evidence of selegiline for depression was rated as very low overall, very low for oral selegiline, and low to moderate for transdermal selegiline. For comparison, meta-analyses of other antidepressants for depression have found a mean effect size of about 0.3 (a small effect), which is similar to that with transdermal selegiline.[6][8][53] WP

In two pivotal regulatory clinical trials of 6 to 8 weeks duration, the selegiline transdermal patch decreased scores on depression rating scales (specifically the 17- and 28-item HDRS (Hamilton Depression Rating Scale)) by 9.0 to 10.9 points, whereas placebo decreased scores by 6.5 to 8.6 points, giving placebo-subtracted differences attributable to selegiline of 2.4 to 2.5 points. A 2013 quantitative review of the transdermal selegiline patch for depression, which pooled the results of these two trials, found that the placebo-subtracted number needed to treat (NNT) was 11 in terms of depression response (>50% reduction in symptoms) and 9 in terms of remission of depression (score of ≤10 on the MADRS (Montgomery–Åsberg Depression Rating Scale)). For comparison, other antidepressants, including fluoxetine, paroxetine, duloxetine, vilazodone, adjunctive aripiprazole, olanzapine/fluoxetine, and extended-release quetiapine, have NNTs ranging from 6 to 8 in terms of depression response and 7 to 14 in terms of depression remission. On the basis of these results, it was concluded that transdermal selegiline has similar effectiveness to other antidepressants. NNTs are measures of effect size and indicate how many individuals would need to be treated in order to encounter one additional outcome of interest. Lower NNTs are better, and NNTs corresponding to Cohen's d effect sizes have been defined as 2.3 for a large effect (d = 0.8), 3.6 for a medium effect (d = 0.5), and 8.9 for a small effect (d = 0.2). The effectiveness of transdermal selegiline for depression relative to side effects and discontinuation was considered to be favorable.[3][7][54] WP

While several large regulatory clinical trials of transdermal selegiline versus placebo for depression have been conducted, there is a lack of trials comparing selegiline to other antidepressants. Although multiple doses of transdermal selegiline were assessed, a dose–response relationship for depression was never established. Transdermal selegiline has shown similar clinical effectiveness in the treatment of atypical depression relative to typical depression and in the treatment of anxious depression relative to non-anxious depression.[45][54][55] WP

Transdermal selegiline does not cause sexual dysfunction and may improve certain domains of sexual function, for instance sexual interest, maintaining interest during sex, and sexual satisfaction. These benefits were apparent in women but not in men. The lack of sexual dysfunction with transdermal selegiline is in contrast to many other antidepressants, such as the selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs), which are associated with high rates of sexual dysfunction.[56][57] WP

Transdermal selegiline patches have been underutilized in the treatment of depression compared to other antidepressants. A variety of factors contributing to this underutilization have been identified. One major factor is the very high cost of transdermal selegiline, which is often not covered by insurance and frequently proves to be prohibitive. Conversely, other widely available antidepressants are much cheaper in comparison.[45][54] WP

Available forms

Selegiline is available in the following three pharmaceutical forms:[44] WP

• Oral tablets and capsules 5 mg (brand names Eldepryl, Jumex, and generics) – indicated for Parkinson's disease[1][9][32] WP
• Orally disintegrating tablets (ODTs) 1.25 mg (brand name Zelapar) – indicated for Parkinson's disease[2][10] WP
• Transdermal patches 6, 9, and 12 mg/24 hours (brand name Emsam) – indicated for major depressive disorder[3][11][12][54][58] WP

The transdermal patch form is also known as the "selegiline transdermal system" or "STS" and is applied once daily. They are 20, 30, or 40 cm² in size and contain a total of 20, 30, or 40 mg selegiline per patch (so 20 mg/20 cm², 30 mg/30 cm², and 40 mg/40 cm²), respectively. The selegiline transdermal patch is a matrix-type adhesive patch with a three-layer structure. It is the only approved non-oral MAOI, having reduced dietary restrictions and side effects in comparison to oral MAOIs, and is also the only approved non-oral first-line antidepressant. The selegiline patch can be useful for those who have difficulty tolerating oral medications.[3][11][12][54][58] WP

Notable users

József Knoll, one of the developers of selegiline, began taking a low 1 mg daily dose of selegiline on January 1, 1989, at the age of 64. He reported in 2012 that this had continued for 22 years uninterrupted. Knoll stated that he had become so fascinated with the possible longevity-promoting effects of selegiline that he had decided to start taking it as a self-experiment. Knoll later died in 2018 at the age of 93.[59][60][61] WP

David Pearce, a British transhumanist philosopher, wrote his self-published book-length internet manifesto The Hedonistic Imperative six weeks after starting to take selegiline.[62][63] WP

Hamilton Morris, a psychoactive drug journalist and researcher, appears to have used selegiline.[64] WP

Sam Bankman-Fried, the founder and former CEO of the FTX cryptocurrency exchange, is known to have used selegiline for depression in the form of the Emsam patch for at least 5 to 10 years. He is also known to have simultaneously taken Adderall for treatment of attention deficit hyperactivity disorder (ADHD) and to have possessed non-pharmaceutical adrafinil, a prodrug of modafinil.[65][66][67] WP

Anti-aging and longevity

József Knoll and his team are credited with having developed selegiline. Although selegiline's development as a potential treatment for Parkinson's disease, Alzheimer's disease, and depression was headed by other teams, Knoll remained at the forefront of research into the potential longevity enhancing effects of selegiline up until his death in 2018. Knoll published his 2012 book How Selegiline ((–)-Deprenyl) Slows Brain Aging wherein he claims that:[59][61][68][69] WP

In humans, maintenance from sexual maturity on (–)-deprenyl (1mg daily) is, for the time being, the most promising prophylactic treatment to fight against the age related decay of behavioral performances, prolonging life, and preventing or delaying the onset of age-related neurodegenerative diseases such as Parkinson's and Alzheimer's. WP

The mechanism of selegiline's longevity-promoting effect has been researched by several groups, including Knoll and his associates at Semmelweis University, Budapest. The drug has been determined to be a catecholaminergic activity enhancer when present in minuscule concentrations far below those at which monoamine oxidase inhibitory activity can be observed, thereby potentiating the release of catecholamine neurotransmitters in response to stimuli. Knoll maintains that micro-doses of selegiline act as a synthetic analogue to a known or unknown trace amine in order to preserve the brain catecholaminergic system, which he perceives as integral to the organism's ability to function in an adaptive, goal-directed and motivated manner during advancing physical age:[5][59] WP

[...] enhancer regulation in the catecholaminergic brain stem neurons play[s] a key role in controlling the uphill period of life and the transition from adolescence to adulthood. The results of our longevity studies support the hypothesis that quality and duration of life rests upon the inborn efficiency of the catecholaminergic brain machinery, i.e. a high performing, long-living individual has a more active, more slowly deteriorating catecholaminergic system than its low performing, shorter living peer. Thus, a better brain engine allows for a better performance and a longer lifespan. [...] WP

Since the catecholaminergic and serotonergic neurons in the brain stem are of key importance in ensuring that the mammalian organism works as a purposeful, motivated, goal-directed entity, it is hard to overestimate the significance of finding safe and efficient means to slow the decay of these systems with passing time. The conclusion that the maintenance on (–)-deprenyl that keeps the catecholaminergic neurons on a higher activity level is a safe and efficient anti-aging therapy follows from the discovery of the enhancer regulation in the catecholaminergic neurons of the brain stem. From the finding that this regulation starts working on a high activity level after weaning and the enhanced activity subsists during the uphill period of life, until sexual hormones dampen the enhancer regulation in the catecholaminergic and serotonergic neurons in the brain stem, and this event signifies the transition from developmental longevity into postdevelopmental longevity, the downhill period of life. WP

Despite findings by Knoll that selegiline can prolong lifespan in rodents by 35% however, other studies have had conflicting findings and have even found increased mortality with selegiline in rodents. In humans with Parkinson's disease, selegiline has been associated with cardiovascular and psychiatric complications and has not been found to reduce mortality in long-term studies. As such, the claimed anti-aging and longevity benefits of selegiline have yet to be substantiated in humans and are controversial and uncertain.[41][42] WP

Nootropic or "smart drug"

Selegiline is considered by some to be a nootropic, otherwise known as a cognitive enhancer or "smart drug", both at clinical and sub-clinical dosages, and has been used off-label and non-medically to improve cognitive performance. It is one of the most popular such agents. Selegiline has been found to have neuroprotective activity against certain neurotoxins and to increase the production of several brain growth factors, such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF). The drug has also been found in animal models to improve learning ability and to help preserve it during ischemia and aging. Despite claims that selegiline and other claimed nootropics have cognitive-enhancing effects however, these effects are controversial and their benefits versus risks are uncertain.[5][37][43][70–74] WP

Veterinary use

In veterinary medicine, selegiline is sold under the brand name Anipryl and is manufactured by Zoetis. It is available in the form of 2, 5, 10, 15, and 30 mg oral tablets for use in animals. Selegiline is used in dogs to treat canine cognitive dysfunction (CCD) and, at higher doses, to treat pituitary-dependent hyperadrenocorticism (PDH).[75][76][77] WP

CCD is a form of dementia that mimics Alzheimer's disease in humans. Geriatric dogs treated with selegiline show improvements in sleeping pattern, reduced urinary incontinence, and increased activity level, with most showing improvements by one month of treatment. Though it is labeled for use in dogs only, selegiline has been used off-label for geriatric cats with cognitive dysfunction.[78–81] WP

PDH is a hormonal disorder and is analogous to pituitary-dependent Cushing's syndrome in humans. Selegiline's effectiveness in treating PDH has been disputed. Theoretically, it works by increasing dopamine levels, which downregulates the secretion of adrenocorticotropic hormone (ACTH) from the brain, eventually leading to reduced levels of cortisol. Some claim that selegiline is only effective at treating PDH caused by lesions in the anterior pituitary (which comprise most canine cases). The greatest sign of improvement is lessening of PDH-related abdominal distention.[75][76][79][81][82] WP

Side effects in dogs are uncommon, but they include vomiting, diarrhea, diminished hearing, salivation, decreased weight, and behavioral changes such as hyperactivity, listlessness, disorientation, and repetitive motions.[77][82] WP

Selegiline has been limitedly studied in large animals like horses and its dosage in these animals has not been established. In preliminary research, a dose of selegiline of 30 mg orally or intravenously in horses had no observable effects on behavior or locomotor activity.[82] WP

The doses of selegiline used in animals are described as extremely high relative to those used in humans (which are ~0.1 mg/kg body weight).[83] WP

Risks and side effects

Contraindications

Selegiline is contraindicated with serotonergic antidepressants including selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs), with serotonergic opioids like meperidine, tramadol, and methadone, with other monoamine oxidase inhibitors (MAOIs) such as linezolid, phenelzine, and tranylcypromine, and with dextromethorphan, St. John's wort, cyclobenzaprine, pentazocine, propoxyphene, and carbamazepine. Combination of selegiline with serotonergic agents may cause serotonin syndrome, while combination of selegiline with adrenergic or sympathomimetic agents like ephedrine or amphetamines may cause hypertensive crisis. Long washout periods are required before starting and stopping these medications with discontinuation or initiation of selegiline.[1][2][3][54] WP

Consumption of tyramine-rich foods can result in hypertensive crisis with selegiline, also known as the "cheese effect" or "cheese reaction" due to the high amounts of tyramine present in some cheeses. Examples of other foods that may have high amounts of tyramine and similar substances include yeast products, chicken liver, snails, pickled herring, red wines, some beers, canned figs, broad beans, chocolate, and cream products.[2][20][35][84] WP

The preceding drug and food contraindications are dependent on selegiline dose and route, and hence are not necessarily absolute contraindications. While high oral doses of selegiline (≥20 mg/day) can cause such interactions, oral doses within the approved clinical range (≤10 mg/day) appear to have little to no risk of these interactions. In addition, the ODT and transdermal forms of selegiline have reduced risks of such interactions compared to the conventional oral form.[1][2][9][10][11][13] WP

Selegiline is also contraindicated in children less than 12 years of age and in people with pheochromocytoma, both due to heightened risk of hypertensive crisis. For all human uses and all forms, selegiline is pregnancy category C, meaning that studies in pregnant animals have shown adverse effects on the fetus but there are no adequate studies in humans.[1][3] WP

Side effects

Side effects of the tablet form in conjunction with levodopa include, in decreasing order of frequency, nausea, hallucinations, confusion, depression, loss of balance, insomnia, increased involuntary movements, agitation, slow or irregular heart rate, delusions, hypertension, new or increased angina pectoris, and syncope. Most of the side effects are due to a high dopamine levels, and can be alleviated by reducing the dose of levodopa. Selegiline can also cause cardiovascular side effects such as orthostatic hypotension, hypertension, atrial fibrillation, and other types of cardiac arrhythmias.[1][4][85] WP

The main side effects of the patch form for depression include application-site reactions, insomnia, dry mouth, dizziness, nervousness, and abnormal dreams. The selegiline patch carries a black box warning about a possible increased risk of suicide, especially for young people, as do all antidepressants since 2007.[3][12][86] WP

Side effects of selegiline that have been identified as occurring significantly more often than with placebo in meta-analyses for psychiatric disorders have included dry mouth (RR (Risk ratio) = 1.58), insomnia (RR (Risk ratio) = 1.61, NNH (Number needed to harm) = 19), and application site reactions with the transdermal form (RR (Risk ratio) = 1.81, NNH (Number needed to harm) = 7). No significant diarrhea, headache, dizziness, nausea, sexual dysfunction, or weight gain were apparent in these meta-analyses.[6][7] WP

Selegiline, including in its oral, ODT, and patch forms, has been found to cause hypotension or orthostatic hypotension in some individuals. In a clinical trial, the rate of systolic orthostatic hypotension was 21% versus 9% with placebo and the rate of diastolic orthostatic hypotension was 12% versus 4% with placebo in people with Parkinson's disease taking the ODT form of selegiline. The risk of hypotension is greater at the start of treatment and in the elderly (3% vs. 0% with placebo). The rate of hypotension or orthostatic hypotension with the selegiline patch was 2.2% versus 0.5% with placebo in clinical trials of people with depression. Significant orthostatic blood pressure changes (≥10 mm Hg decrease) occurred in 9.8% versus 6.7% with placebo, but most of these cases were asymptomatic and heart rate was unchanged. The rates of other orthostatic hypotension-related side effects in this population were dizziness or vertigo 4.9% versus 3.1% with placebo and fainting 0.5% versus 0.0% with placebo. It is said that orthostatic hypotension is rarely seen with the selegiline transdermal patch compared to oral MAOIs. Caution is advised against rapidly rising after sitting or lying, especially after prolonged periods or at the start of treatment, as this can result in fainting. Falls are of particular concern in the elderly. MAOIs like selegiline may lower blood pressure by increasing dopamine levels and activating dopamine receptors, by increasing levels of the false neurotransmitter octopamine, and/or by other mechanisms.[1][2][3][12][15][45][87][88] WP

Meta-analyses published in the 1990s found that the addition of selegiline to levodopa increased mortality in people with Parkinson's disease. However, several subsequent meta-analyses with more trials and patients found no increase in mortality with selegiline added to levodopa. If selegiline does increase mortality, it has been theorized that this may be due to cardiovascular side effects, such as its amphetamine-related sympathomimetic effects and its MAO inhibition-related hypotension. Although selegiline does not seem to increase mortality, it appears to worsen cognition in people with Parkinson's disease over time. Conversely, rasagiline does not seem to do so and can enhance cognition.[15][89–92] WP

Rarely, selegiline has been reported to induce or exacerbate impulse control disorders, pathological gambling, hypersexuality, and paraphilias in people with Parkinson's disease. However, MAO-B inhibitors like selegiline causing impulse control disorders is uncommon, controversial, and less frequent than with dopamine receptor agonists like pramipexole. Impulse control disorders with dopaminergic agents have been linked specifically to activation of dopamine D₃ receptors in the globus pallidus. Selegiline has also been reported to activate or worsen rapid eye movement (REM) sleep behavior disorder (RBD) in some people with Parkinson's disease.[93–107] WP

Selegiline has shown little or no misuse potential in humans or monkeys. Likewise, it has no dependence potential in rodents. This is in spite of its amphetamine active metabolites, levomethamphetamine and levoamphetamine, and is in contrast to agents like dextroamphetamine and dextromethamphetamine. However, selegiline can strongly potentiate the reinforcing effects of exogenous β-phenethylamine by inhibiting its MAO-B-mediated metabolism. Misuse of the combination of selegiline and β-phenethylamine has been reported.[14–17][108–112] WP

Overdose

Little information is available about clinically significant selegiline overdose. The drug has been studied clinically at doses as high as 60 mg/day orally, 10 mg/day as an ODT, and 12 mg/24 hours as a transdermal patch. In addition, deprenyl (the racemic form) has been clinically studied orally at doses as large as 100 mg/day. During clinical development of oral selegiline, some individuals who were exposed to doses of 600 mg developed severe hypotension and psychomotor agitation. Overdose may result in non-selective inhibition of both MAO-A and MAO-B and may be similar to overdose of other non-selective monoamine oxidase inhibitors (MAOIs) like phenelzine, isocarboxazid, and tranylcypromine. Serotonin syndrome, hypertensive crisis, and/or death may occur with overdose. No specific antidote to selegiline overdose is available.[1][2][3][6][10][11][19][113] WP

Addiction

Selegiline has been evaluated for smoking cessation both as a monotherapy and in combination with nicotine replacement therapy in five clinical studies. However, it is limitedly or not effective for this use. It was also evaluated for treatment of cocaine dependence in one study, but was similarly not effective. Studies are mixed on whether selegiline, at MAO-B-selective doses, reduces the effects of cocaine in humans. Selegiline, also at an MAO-B-selective dosage, did not modify or potentiate the pharmacological effects of intravenous methamphetamine in a small clinical study.[6][114–124] WP

Neurotoxicity

Selegiline has been reported to protect against the damage caused by the potent dopaminergic and/or noradrenergic neurotoxins 6-hydroxydopamine (6-OHDA), N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in animals. Conversely, selegiline is ineffective in protecting against the serotonergic and noradrenergic neurotoxin 5,7-dihydroxytryptamine (5,7-DHT).[19][125–130] WP

Selegiline has also been reported to protect against methylenedioxymethamphetamine (MDMA)-induced serotonergic neurotoxicity in rodents. The serotonergic neurotoxicity of MDMA appears to be dependent on release of dopamine and its subsequent metabolism by MAO-B within serotonergic neurons into hydroxyl radicals, which is blocked by MAO-B inhibition. Likewise, selegiline prevented the serotonergic neurotoxicity of a combination of methylenedioxyaminoindane (MDAI) and dextroamphetamine.[131–137] WP

Conversely, selegiline failed to reduce the serotonergic neurotoxicity caused by fenfluramine and either did not affect or potentiated the serotonergic neurotoxicity caused by para-chloroamphetamine (PCA). In addition, findings are mixed and conflicting on whether selegiline prevents amphetamine- and methamphetamine-induced dopaminergic neurotoxicity in rodents.[127][138–144] WP

Although MAO-B-selective doses of selegiline protect against MDMA-induced serotonergic neurotoxicity in rodents, combination of amphetamines like MDMA with MAOIs, including selegiline, can produce serious complications, including serotonin syndrome, hypertensive crisis, and death.[145][146] WP

Interactions

Serotonin syndrome and hypertensive crisis

Both the oral and patch forms of selegiline come with strong warnings against combining it with drugs that could produce serotonin syndrome, such as selective serotonin reuptake inhibitors (SSRIs) and the cough medicine dextromethorphan. Selegiline in combination with the opioid analgesic pethidine is not recommended, as it can lead to severe adverse effects. Several other synthetic opioids such as tramadol and methadone, as well as various triptans, are also contraindicated due to potential for serotonin syndrome.[1][3][147][148][149] WP

All three forms of selegiline carry warnings about food restrictions to avoid hypertensive crisis that are associated with MAOIs. The patch form was created in part to overcome food restrictions; clinical trials showed that it was successful. Additionally, in post-marketing surveillance from April 2006 to October 2010, only 13 self-reports of possible hypertensive events or hypertension were made out of 29,141 exposures to the drug, and none were accompanied by objective clinical data. The lowest dose of the patch method of delivery, 6 mg/24 hours, does not require any dietary restrictions. Higher doses of the patch and oral formulations, whether in combination with the older non-selective MAOIs or in combination with the reversible MAO-A inhibitor (RIMA) moclobemide, require a low-tyramine diet.[1][2][3][7][147][150] WP

A study found that selegiline in transdermal patch form did not importantly modify the pharmacodynamic effects or pharmacokinetics of the sympathomimetic agents pseudoephedrine and phenylpropanolamine. Likewise, oral selegiline at an MAO-B-selective dosage did not appear to modify the pharmacodynamic effects or pharmacokinetics of intravenous methamphetamine in another study. Conversely, selegiline, also at MAO-B-selective doses, has been found to reduce the physiological and euphoric subjective effects of cocaine whilst not affecting its pharmacokinetics in some studies but not in others. Cautious safe combination of MAOIs like selegiline with stimulants like lisdexamfetamine has been reported. However, a hypertensive crisis with selegiline and ephedrine has also been reported. The selegiline drug labels warn about combination of selegiline with indirectly acting sympathomimetic agents, like amphetamines, ephedrine, pseudoephedrine, and phenylpropanolamine, due to the potential risk of hypertensive crisis, and recommend monitoring blood pressure with such combinations. The combination of selegiline with certain other medications, like phenylephrine and buspirone, is also warned against for similar reasons. In the case of phenylephrine, this drug is substantially metabolized by monoamine oxidase, including by both MAO-A and MAO-B. Selegiline can interact with exogenous dopamine, which is metabolized by MAO-A and MAO-B, and result in hypertensive crisis as well.[1][2][3][11][58][87][117–124][151–159] WP

Besides norepinephrine releasing agents, selective norepinephrine reuptake inhibitors (NRIs) may be safe in combination with MAOIs like selegiline. Potent NRIs, such as reboxetine, desipramine, protriptyline, and nortriptyline, can reduce or block the pressor effects of tyramine, including in those taking MAOIs. This is by inhibiting the norepinephrine transporter (NET) and preventing entry of tyramine into presynaptic noradrenergic neurons where tyramine induces the release of norepinephrine. As a result, NRIs may reduce the risk of tyramine-related hypertensive crisis in people taking MAOIs. Norepinephrine–dopamine reuptake inhibitors (NDRIs), like methylphenidate and bupropion, are also considered to be safe in combination with MAOIs. However, initiation at low doses and slow upward dose titration is advisable in the case of both NRIs and NDRIs due to possible potentiation of their effects and side effects by MAOIs.[160–163] WP

Selegiline may potentiate the effects of serotonergic psychedelics that are MAO-B substrates, such as 2C drugs like 2C-B, 2C-I, and 2C-E.[164][165][166] WP

Cytochrome P450 inhibitors and inducers

The cytochrome P450 enzymes involved in the metabolism of selegiline have not been fully elucidated. CYP2D6 and CYP2C19 metabolizer phenotypes did not significantly affect the pharmacokinetics of selegiline, suggesting that these enzymes are minimally involved in its metabolism and that inhibitors and inducers of these enzymes would not importantly affect its pharmacokinetics. However, although most pharmacokinetic variables were unaffected, overall exposure to selegiline's metabolite levomethamphetamine was 46% higher in CYP2D6 poor metabolizers compared to extensive metabolizers and exposure to its metabolite desmethylselegiline was 68% higher in CYP2C19 poor metabolizers compared to extensive metabolizers. As with the cases of CYP2D6 and CYP2C19, the strong CYP3A4 and CYP3A5 inhibitor itraconazole has minimal impact on the pharmacokinetics of selegiline, suggesting lack of major involvement of this enzyme as well. On the other hand, the anticonvulsant carbamazepine, which is known to act as a strong inducer of CYP3A enzymes, has paradoxically been found to increase exposure to selegiline and its metabolites levomethamphetamine and levoamphetamine by approximately 2-fold (with selegiline used as the transdermal patch form). One enzyme thought to be majorly involved in the metabolism of selegiline based on in-vitro studies is CYP2B6. However, there are no clinical studies of different CYP2B6 metabolizer phenotypes or of CYP2B6 inhibitors or inducers on the pharmacokinetics of selegiline. In addition to CYP2B6, CYP2A6 may be involved in the metabolism of selegiline to a lesser extent.[2][3][9][11][30][35][167–173] WP

Birth control pills containing the synthetic estrogen ethinylestradiol and a progestin like gestodene or levonorgestrel have been found to increase peak levels and overall exposure to oral selegiline by 10- to 20-fold. High levels of selegiline can lead to loss of MAO-B selectivity and inhibition of MAO-A as well. This increases susceptibility to side effects and interactions of non-selective monoamine oxidase inhibitors (MAOIs), such as tyramine-induced hypertensive crisis and serotonin toxicity when combined with serotonergic medications. However, this study had a small sample size of four individuals as well as other methodological limitations. The precise mechanism underlying the interaction is unknown, but is likely related to cytochrome P450 inhibition and consequent inhibition of selegiline first-pass metabolism by ethinylestradiol. In contrast to birth control pills containing ethinylestradiol, menopausal hormone therapy with estradiol and levonorgestrel did not modify peak levels of selegiline and only modestly increased overall exposure (+59%). Hence, menopausal hormone therapy does not pose the same risk of interaction as ethinylestradiol-containing birth control pills when taken together with selegiline.[167][174][175][176] WP

Overall exposure to selegiline with oral selegiline has been found to be 23-fold lower in people taking anticonvulsants known to strongly activate drug-metabolizing enzymes. The anticonvulsants included phenobarbital, phenytoin, carbamazepine, and amobarbital. In a previous study however, carbamazepine specifically did not reduce selegiline exposure. Phenobarbital and certain other anticonvulsants are known to strongly induce CYP2B6, one of the major enzymes believed to be involved in selegiline metabolism. As such, it was concluded that strong CYP2B6 induction was most likely responsible for the dramatically reduced exposure to selegiline observed in the study.[3][11][177] WP

Selegiline inhibition of cytochrome P450 enzymes

Selegiline has been reported to inhibit several cytochrome P450 enzymes, including CYP2D6, CYP3A4/5, CYP2C19, CYP2B6, and CYP2A6. It is a mechanism-based inhibitor (suicide inhibitor) of CYP2B6 and has been said to "potently" or "strongly" inhibit this enzyme in vitro. It may inhibit the metabolism of bupropion, a major CYP2B6 substrate, into its active metabolite hydroxybupropion. However, a study predicted that inhibition of CYP2B6 by selegiline would non-significantly affect exposure to bupropion. Selegiline has not been listed or described as a clinically significant CYP2B6 inhibitor by the Food and Drug Administration (FDA) as of 2023. One small study observing three patients found that selegiline was safe and well-tolerated in combination with bupropion. In addition to CYP2B6 and other cytochrome P450 enzymes, selegiline is a potent mechanism-based inhibitor of CYP2A6 and may increase exposure to nicotine (a major CYP2A6 substrate). By inhibiting cytochrome P450 enzymes like CYP2B6 and CYP1A2, selegiline may inhibit its own metabolism and thereby interact with itself.[3][171][178–185] WP

Other interactions

Dopamine antagonists like antipsychotics or metoclopramide, which block dopamine receptors and thereby antagonize the dopaminergic effects of selegiline, could potentially reduce the effectiveness of the medication. Dopamine-depleting agents like reserpine and tetrabenazine, by reducing dopamine levels, can also oppose the effectiveness of dopaminergic medications like selegiline.[2][186] WP

Pharmacology

Pharmacodynamics

Selegiline has multiple known mechanisms of action in terms of its pharmacodynamic activity. It is most notably an irreversible monoamine oxidase (MAO) inhibitor (MAOI). More specifically, it is a selective inhibitor of monoamine oxidase B (MAO-B) at lower doses and with an IC₅₀ of 6.8nM (≤10 mg/day) but additionally inhibits monoamine oxidase A (MAO-A) at higher doses (≥20 mg/day) and possesses an IC₅₀ of 23μM. MAO-B inhibition is thought to result in increased levels of dopamine and β-phenethylamine, whereas MAO-A inhibition results in increased levels of serotonin, norepinephrine, and dopamine. Selegiline is also a catecholaminergic activity enhancer (CAE) and enhances the action potential-evoked release of norepinephrine and dopamine. The CAE activity of selegiline may be mediated by TAAR1 agonism. Both the MAOI activity and CAE activity of selegiline may be involved in its therapeutic effects in the treatment of Parkinson's disease and depression. According to József Knoll and other researchers, selegiline might have dopaminergic neuroprotective effects, might be able to modestly slow the rate of aging-related dopaminergic neurodegeneration, and might thereby have a disease-modifying effect in Parkinson's disease and antiaging effects generally. However, these theoretical effects of selegiline have not been clearly demonstrated in humans as of present and remain to be substantiated. Through its active metabolites levomethamphetamine (L-MA) and levoamphetamine (L-A), selegiline acts as a weak norepinephrine and/or dopamine releasing agent (NDRA). The clinical significance of this action is unclear, but it may be relevant to the effects and side effects of selegiline, especially at higher doses. Its active metabolite desmethylselegiline (DMS) also has MAOI and CAE activity and likely contributes to its effects as well. Levels of selegiline's metabolites are much lower with the ODT and transdermal patch forms of selegiline than with the oral form and this may result in differences in its effects and side effects.[5][9][10][11][13][16][19–29][42][52][59][187–197] WP

Pharmacokinetics

Selegiline is available in forms for use by multiple different routes of administration and its pharmacokinetics vary by route. The bioavailability of the oral form of selegiline is 4–10%, of the ODT is 5 to 8 times that of the oral form, and of the transdermal patch is 75%. The time to peak levels of selegiline with oral administration is about 0.5 to 1.5 hours. The plasma protein binding of selegiline is 85–90%. It is metabolized extensively in the liver by the cytochrome P450 enzyme CYP2B6 among other enzymes. Metabolites of selegiline include desmethylselegiline (DMS), levomethamphetamine (L-MA), and levoamphetamine (L-A). The oral form of selegiline is subject to strong first-pass metabolism and levels of the metabolites of selegiline are much lower with the ODT and transdermal patch forms than with the oral form. The elimination half-lives of selegiline and its metabolites range from 1.2 to 10 hours for selegiline, 2.2 to 9.5 hours for DMS, 14 to 21 hours for levomethamphetamine, and 16 to 18 hours for levoamphetamine. Selegiline and its metabolites are eliminated mainly in urine (87% in urine and 15% in feces via oral administration), with its metabolites accounting for virtually all of the eliminated material in the case of the oral form. Hepatic impairment and renal impairment have been found to dramatically increase exposure to selegiline.[1][2][3][9][10][11][13][19][20][34][44][58][83][167][172][177][198–203] WP

Research

Depression

Selegiline has been clinically studied in combination with oral L-phenylalanine or β-phenethylamine in the treatment of depression and was reported to be effective. L-Phenylalanine is known to be metabolized into β-phenethylamine, selegiline is known to strongly inhibit the metabolism of β-phenethylamine, and β-phenethylamine has been implicated in having psychostimulant-like mood-lifting effects.[19][26][204–207] WP

Social anxiety

A small clinical study found that oral selegiline (10 mg/day) reduced symptoms of social anxiety disorder. The effectiveness was modest, with a reduction in social anxiety scores from baseline of 32% over 6 weeks of treatment. It was seemingly less effective than certain other agents used in the treatment of social anxiety, such as the non-selective MAOI phenelzine (45% symptom reduction) and the benzodiazepine clonazepam (51% symptom reduction), though it was similar to the SSRI sertraline (32% symptom decrease).[6][58][208] WP

ADHD

Selegiline has been limitedly studied in the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. In a small randomized trial of selegiline for treatment of ADHD in children, there were improvements in attention, hyperactivity, and learning/memory performance but not in impulsivity. A small clinical randomized trial compared selegiline to methylphenidate, a first line treatment for ADHD, and reported equivalent efficacy as assessed by parent and teacher ratings. In another small randomized controlled trial of selegiline for the treatment of adult ADHD, a high dose of the medication for 6 weeks was not significantly more effective than placebo in improving symptoms. Selegiline in its transdermal patch form (brand name Emsam) has also been assessed in the treatment of ADHD in children and adolescents in a small open-label pilot study sponsored by the manufacturer in 2003. However, there was a high rate of discontinuation and development was not further pursued.[6][58][209–216] WP

Motivational disorders

Selegiline has been found to produce pro-motivational effects and to reverse motivational deficits in rodents. In case reports and small clinical studies, selegiline has been reported to improve disorders of diminished motivation like apathy and abulia due to conditions such as traumatic brain injury. In accordance with the preceding findings, selegiline, along with other dopaminergic and activating agents, may be useful in the treatment of disorders of diminished motivation, including apathy, abulia, and akinetic mutism.[217–226] WP

Sexual dysfunction

Selegiline has been assessed for treatment of sexual dysfunction induced by antipsychotics in people with schizophrenia, but was not effective in a single small clinical study. It also did not improve sexual function in men with depression, but did improve several domains of sexual function in women with depression.[56][227][228] WP

Psychosis

Selegiline has been studied as an adjunct to antipsychotics in the treatment of schizophrenia in four clinical studies. However, it failed to significantly reduce positive or negative symptoms of schizophrenia in meta-analyses of these studies.[6][229] WP

Excessive sleepiness

Selegiline has been evaluated for the treatment of narcolepsy in three small clinical studies. It was found to be effective in these studies. A dosage of 10 mg/day had no effect on symptoms, but 20 to 30 mg/day improved alertness, mood, and somewhat reduced cataplexy, clinical effects that have been described as comparable to the same dosages of amphetamine. Animal research indicates that the beneficial effects of high doses of selegiline in narcolepsy are likely due to conversion into its active metabolites, levoamphetamine and levomethamphetamine. Selegiline has also been evaluated for treatment of hypersomnia (excessive sleeping or sleepiness) in people with myotonic dystrophy, but its effectiveness was very uncertain.[230–233] WP

Periodic limb movement disorder

Selegiline has been studied in the treatment of periodic limb movement disorder (PLMD) in a single small open-label clinical study. It was reported to be effective as assessed by polysomnography, reducing periodic limb movements during sleep by about 60%. Selegiline has not been studied for the related condition restless legs syndrome (RLS) as of 2023. The drug has not been studied well enough in PLMD or RLS to be widely used in their treatment.[234][235][236] WP

Tardive dyskinedia

Selegiline was studied in the treatment of antipsychotic-induced tardive dyskinesia in one small clinical study, but was ineffective.[237] WP

Dementia and stroke

Selegiline has also been used off-label as a palliative treatment for dementia in Alzheimer's disease. However, its clinical effectiveness is limited or lacking for this use. It was also ineffective in the treatment of Lewy body dementia. Selegiline has been used to support motor rehabilitation in stroke recovery, but evidence for this use is inadequate and no recommendation can be made for or against it.[47][238–243] WP

Disorders of consciousness

Selegiline has been studied in patients with disorders of consciousness, such as minimally conscious state, persistent vegetative state, and persistent coma, in a small open-label clinical study. It was found to be effective in enhancing arousal and promoting recovery of consciousness in some of these individuals.[244][245] WP

Other formulations

The original oral formulation of selegiline was developed for the treatment of depression. However, it ended up being developed and approved for the treatment of Parkinson's disease instead. In any case, oral selegiline has been widely used off-label to treat depression. The transdermal patch form of selegiline was developed and approved specifically for the treatment of depression. It was also under development for the treatment of Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), cognition disorders, and Parkinson's disease, but development for these indications was discontinued. The ODT form of selegiline was developed and licensed exclusively for the treatment of Parkinson's disease.[1][2][3][6][10][11][32][38][58][246][247] WP

History

History

Following the discovery in 1952 that the tuberculosis drug iproniazid elevated the mood of people taking it, and the subsequent discovery that the effect was likely due to inhibition of monoamine oxidase (MAO) and elevation of monoamine neurotransmitters in the brain, many people and companies started trying to discover monoamine oxidase inhibitors (MAOIs) to use as antidepressants. Deprenyl, the racemic form of selegiline, was synthesized and discovered by Zoltan Ecseri at the Chinoin Pharmaceutical Company (part of Sanofi since 1993) in Budapest, Hungary. Chinoin received a patent on the drug in 1962 and the compound was first published in the scientific literature in English in 1965. Chinoin researchers had been studying substituted amphetamines since 1960, and decided to try synthesizing amphetamines that acted as MAOIs. It had been known that methamphetamine was a reversible inhibitor of MAO. Deprenyl, also known as N-propargyl-N-methylamphetamine, is closely related to and inspired by pargyline (N-propargyl-N-methylbenzylamine), another MAOI that had been synthesized earlier. Deprenyl was initially referred to by the chemical name phenylisopropylmethylpropinylamine and the developmental code name E-250. Work on the biology and effects of E-250 in animals and humans was conducted by a group led by József Knoll at Semmelweis University, which was also in Budapest.[20][23][84][248–251] WP

Deprenyl is a racemic compound (a mixture of two isomers called enantiomers). The racemic form has mild amphetamine-like psychostimulant effects that are diminished compared to those of amphetamine but are still present. The levorotatory enantiomer has further reduced stimulant effects, and further work, published in 1967, determined that the levorotatory enantiomer was a more potent MAOI than the dextrorotatory enantiomer. As a result, subsequent work was done with the single enantiomer L-deprenyl. In 1968, it was discovered by J. P. Johnston that monoamine oxidase exists in multiple forms. In 1971, Knoll showed that selegiline highly selectively inhibits the B-isoform of monoamine oxidase (MAO-B) and proposed that it is unlikely to cause the infamous "cheese effect" (hypertensive crisis resulting from consuming foods containing tyramine) that occurs with non-selective MAOIs. The lack of potentiation of tyramine effect by deprenyl had previously been reported in 1966 and 1968 studies, but could not be mechanistically explained until after the existence of multiple forms of MAO was discovered. Selegiline was the first selective MAO-B inhibitor to be discovered and hence is described as prototypical of these agents.[20][34][35][36][60][84][252–255] WP

Deprenyl and selegiline were initially studied as antidepressants for treatment of depression. Deprenyl was first found to be effective for depression from 1965 to 1967, while selegiline was first found to be effective for depression in 1971 and this was further corroborated in 1980. A 1984 study that combined selegiline with phenylalanine reported remarkably high effectiveness in the treatment of depression similar to that with electroconvulsive therapy (ECT). However, selegiline in its original oral form was never further developed or approved for the treatment of depression.[38][205][250][256–259] WP

A few years after the discovery that selegiline was a selective MAO-B inhibitor, two Parkinson's disease researchers based in Vienna, Peter Riederer and Walther Birkmayer, realized that selegiline could be useful in Parkinson's disease. One of their colleagues, Moussa B. H. Youdim, visited Knoll in Budapest and took selegiline from him to Vienna. In 1975, Birkmayer's group published the first paper on the effect of selegiline in Parkinson's disease.[60][260] WP

Speculation, by József Knoll, that selegiline could be useful as an anti-aging and pro-sexual agent, began in the 1980s. The New York Times reported that selegiline was being used non-medically as a "smart drug" by 1992.[84][261–265] WP

Selegiline was first introduced for clinical use in Hungary in 1977. It was approved in the oral pill form under the brand name Jumex to treat Parkinson's disease. The drug was then introduced in the United Kingdom in 1982. In 1987, Somerset Pharmaceuticals in New Jersey, which had acquired the rights to develop selegiline in the United States, filed a New Drug Application (NDA) with the Food and Drug Administration (FDA) to market the drug for Parkinson's disease in this country. While the NDA was under review, Somerset was acquired in a joint venture by two generic drug companies, Mylan and Bolan Pharmaceuticals. Selegiline was approved for Parkinson's disease by the FDA in 1989.[32][33] WP

It had been known since the mid-1960s that high doses of deprenyl had psychostimulant effects. Selegiline was first shown to metabolize into levomethamphetamine and levoamphetamine in humans in 1978. The involvement of these metabolites in the effects and side effects of selegiline has remained controversial and unresolved in the decades afterwards. In any case, concerns about these metabolites have contributed to the development of newer MAO-B inhibitors like rasagiline and safinamide that lack such metabolites.[16][19][20][28][250][257][266][267] WP

The catecholaminergic activity enhancer (CAE) effects of selegiline became well-characterized and distinctly named in 1994. These effects had been observed much earlier, dating back to the 1960s and 1970s, but were not properly distinguished from the other actions of selegiline, like MAO-B inhibition, until the 1990s. More potent, selective, and/or expansive monoaminergic activity enhancers (MAEs), like phenylpropylaminopentane (PPAP) and benzofuranylpropylaminopentane (BPAP), were derived from selegiline and other compounds and were first described in 1988 and 1999, respectively. These drugs had been proposed for potential treatment of psychiatric disorders like depression as well as for Parkinson's disease and Alzheimer's disease, but were never developed or marketed.[5][13][22][23][24][26][38][188][189][196][268–273] WP

In the 1990s, J. Alexander Bodkin at McLean Hospital, an affiliate of Harvard Medical School, began a collaboration with Somerset to develop delivery of selegiline via a transdermal patch in order to avoid the well known dietary restrictions of MAOIs. Somerset obtained FDA approval to market the patch for depression in 2006. Similarly, the orally disintegrating tablet (ODT) form of selegiline, marketed under the brand name Zelapar, was approved for Parkinson's disease in the United States in 2006 and in the European Union in 2010.[32][264][274][275][276] WP

Binding to and agonism of the trace amine-associated receptors (TAARs) as the mechanism responsible for the MAE effects of selegiline and related MAEs like PPAP and BPAP was first suggested in the early 2000s following the discovery of the TAARs. Activation of the TAAR1 as the mechanism of the MAE effects was first clearly substantiated in 2022.[25][26][27][189][277] WP

Legal status

Names

Selegiline is the generic name of the drug and its INN (International Nonproprietary Name), BAN (British Approved Name), and DCF (Dénomination Commune Française), while selegiline hydrochloride is the USAN (United States Adopted Name). The word "selegiline" is pronounced /səˈlɛdʒᵻliːn/ or as "seh-LEH-ji-leen". Selegiline is also known as L-deprenyl, L-deprenil, L-deprenalin, L-deprenaline, L-phenylisopropylmethylpropinylamine, and L-E-250. It should not be confused with the racemic form, deprenyl (E-250), or with the dextrorotatory enantiomer, D-deprenyl, which are distinct substances.[5][31][250][278–282] WP⚠ The source gives a pronunciation guide here that is not shown.

Major brand names of selegiline include Eldepryl, Jumex, and Movergan (oral tablet and/or capsule), Zelapar (orally disintegrating tablet or ODT), and Emsam (transdermal patch). Selegiline has been marketed under more than 70 brand names worldwide. The brand name "Emsam" was derived from the names of two children, Emily and Samuel, of one of the executives at Somerset Pharmaceuticals, the developer of Emsam.[4][54][83][280][283][284] WP

Generic forms

Generic forms of oral selegiline are available in the United States. However, generic forms of the orally disintegrating tablet and the transdermal patch are not available in this country. The latter formulations of selegiline are very expensive, and this can be prohibitive to their use. There has been poor insurance coverage of the transdermal patch form for depression, with insurance companies often requiring patients to first fail to respond to one or two other antidepressants and to be responsible for larger copayments. It is expected that generics of the transdermal patch will become available at some point in the future.[44][45][285] WP

Availability

Conventional oral selegiline (brand names Eldepryl, Jumex) is widely marketed throughout the world, including in over 70 countries. Conversely, the selegiline transdermal patch (brand name Emsam) is only marketed in the United States, while the selegiline orally disintegrating tablet (brand name Zelapar) is marketed in the United States, the United Kingdom, and the European Union.[4][5][32][280][283] WP

Fictional representations

In Gregg Hurwitz's novel Out of the Dark, selegiline (Emsam) and tyramine-containing food were used to assassinate the president of the United States.[286] WP

Internet vendors

Selegiline in non-pharmaceutical form is sold on the Internet without a prescription by online vendors for uses such as purported cognitive enhancement (i.e., as a so-called "smart drug" or nootropic) and anti-aging effects. It is widely available for such purposes, for instance under informal brand names like Dep-Pro, Selepryl, and Cyprenil, which are oral liquid solutions of selegiline at a concentration of 1 mg per drop.[43][59][196][287][288] WP

Presence in ecstasy

In his 1993 book E for Ecstasy examining the uses of the street drug ecstasy in the United Kingdom, the writer, activist, and ecstasy advocate Nicholas Saunders highlighted test results showing that certain consignments of the drug also contained selegiline. Consignments of ecstasy known as "Strawberry" contained what Saunders described as a "potentially dangerous combination of ketamine, ephedrine and selegiline," as did a consignment of "Sitting Duck" Ecstasy tablets.[289][290] WP

Doping in sport

Selegline is on the World Anti-Doping Agency (WADA)'s list of prohibited substances. It is classified as a "stimulant" in this list, along with various amphetamines, methylphenidate, adrenergic sympathomimetics, modafinil, and other agents. A review of the pharmacology of WADA prohibited substances noted that although selegiline is classified as a stimulant in the WADA prohibited substances list and stimulants can enhance physical performance, selegiline was seemingly included in the list not because of any short-term stimulant effects of its own, but rather because it metabolizes into small amounts of levomethamphetamine and levoamphetamine and can produce false positives for amphetamines on drug tests. In any case, levomethamphetamine and levoamphetamine are catecholamine releasing agents and can produce sympathomimetic and psychostimulant effects with sufficiently high exposure. Such actions may have performance-enhancing effects.[291–294] WP

Regulatory status

Selegiline is a prescription drug. It is not specifically a controlled substance in the United States and hence is not an illegal drug. However, deprenyl and selegiline are controlled substances in Japan. They are classified as "Stimulants", alongside a variety of other amphetamines, under Article 2 of Japan's Narcotics and Psychotropics Control Law. Selegiline is known to metabolize into small amounts of levoamphetamine and levomethamphetamine but is thought to have little to no misuse potential or dependence liability.[1][2][3][14–18][108][295] WP

Chemistry

Formula

C13H17N PC

CAS number

14611-51-9 PC

Molar mass (g/mol)

187.28 PC

IUPAC name (computed by PubChem)

(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine PC

SMILES

C[C@H](CC1=CC=CC=C1)N(C)CC#C PC

InChIKey

MEZLKOACVSPNER-GFCCVEGCSA-N PC

PubChem CID

26757

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency ELDEPRYL® (Selegiline Hydrochloride) Tablets, USP Label. January 2008
2. Journal / agency ZELAPAR® (Selegiline Hydrochloride) Orally Disintegrating Tablets. July 2021
3. Journal / agency EMSAM® (Selegiline Transdermal System) Label. July 2017
4. Other Selegiline
5. Journal / agency Miklya I. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015). Molecular Psychiatry. November 2016. doi:10.1038/mp.2016.127 · PMID 27480491
6. Journal / agency Rossano F, Caiazza C, Sobrino A, Solini N, Vellucci A, Zotti N, Fornaro M, Gillman K, Cattaneo CI, Van den Eynde V, Birkenhager TK, Ruhé HG, Stahl S, Iasevoli F, de Bartolomeis A. Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations. Eur Neuropsychopharmacol. July 2023. doi:10.1016/j.euroneuro.2023.03.012 · PMID 37087864
7. Journal / agency Citrome L, Goldberg JF, Portland KB. Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders. November 2013. doi:10.1016/j.jad.2013.06.027 · PMID 23890583
8. Journal / agency Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. April 2018. doi:10.1016/S0140-6736(17)32802-7 · PMID 29477251 · PMC5889788
9. Journal / agency Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet. August 1997. doi:10.2165/00003088-199733020-00002 · PMID 9260033
10. Journal / agency Poston KL, Waters C. Zydis selegiline in the management of Parkinson's disease. Expert Opin Pharmacother. October 2007. doi:10.1517/14656566.8.15.2615 · PMID 17931095
11. Journal / agency Lee KC, Chen JJ. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment. November 2007. doi:10.2147/ndt.s12160200 · PMID 19300583 · PMC2656289
12. Journal / agency Robinson DS, Amsterdam JD. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability. J Affect Disord. January 2008. doi:10.1016/j.jad.2007.04.024 · PMID 17568687
13. Journal / agency Gerlach M, Youdim MB, Riederer P. Pharmacology of selegiline. Neurology. December 1996. doi:10.1212/wnl.47.6_suppl_3.137s · PMID 8959982
14. Journal / agency Finberg JP, Rabey JM. Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology. Front Pharmacol. 2016. doi:10.3389/fphar.2016.00340 · PMID 27803666 · PMC5067815
15. Journal / agency Fabbrini G, Abbruzzese G, Marconi S, Zappia M. Selegiline: a reappraisal of its role in Parkinson disease. Clin Neuropharmacol. 2012. doi:10.1097/WNF.0b013e318255838b · PMID 22592509
16. Journal / agency Yasar S, Goldberg JP, Goldberg SR. Deprenyl — Past and Future. January 1, 1996. doi:10.1007/978-3-7091-7494-4_6 · PMID 8988462
17. Journal / agency Nickel B, Szelenyi I, Schulze G. Evaluation of physical dependence liability of l-deprenyl (selegiline) in animals. Clin Pharmacol Ther. December 1994. doi:10.1038/clpt.1994.206 · PMID 7995018
18. Other KEGG DRUG: Narcotics and Psychotropics in Japan. 26 April 2024
19. Journal / agency Heinonen EH, Lammintausta R. A review of the pharmacology of selegiline. Acta Neurologica Scandinavica. Supplementum. 1991. doi:10.1111/j.1600-0404.1991.tb05020.x · PMID 1686954
20. Journal / agency Magyar K. Monoamine Oxidases and Their Inhibitors. 2011. doi:10.1016/B978-0-12-386467-3.00004-2 · PMID 21971003
21. Journal / agency Knoll J. Istoriia deprenil--pervogo selektivnogo ingibitora monoaminoksidazy tipa B. Voprosy Meditsinskoi Khimii. 1997. PMID 9503565
22. Journal / agency Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol. February 1998. doi:10.1111/j.1600-0773.1998.tb01399.x · PMID 9498233
23. Other Miklya I. The History of Selegiline/(-)-Deprenyl the First Selective Inhibitor of B-Type Monoamine Oxidase and The First Synthetic Catecholaminergic Activity Enhancer Substance. March 13, 2014
24. Journal / agency Gaszner P, Miklya I. Major depression and the synthetic enhancer substances, (-)-deprenyl and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane. Prog Neuropsychopharmacol Biol Psychiatry. January 2006. doi:10.1016/j.pnpbp.2005.06.004 · PMID 16023777
25. Journal / agency Harsing LG, Timar J, Miklya I. Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline. Int J Mol Sci. August 2023. doi:10.3390/ijms241713334 · PMID 37686140 · PMC10487936
26. Journal / agency Shimazu S, Miklya I. Pharmacological studies with endogenous enhancer substances: β-phenylethylamine, tryptamine, and their synthetic derivatives. Prog Neuropsychopharmacol Biol Psychiatry. May 2004. doi:10.1016/j.pnpbp.2003.11.016 · PMID 15093948
27. Journal / agency Berry MD. The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Rev Recent Clin Trials. January 2007. doi:10.2174/157488707779318107 · PMID 18473983
28. Journal / agency Gerlach M, Reichmann H, Riederer P. A critical review of evidence for preclinical differences between rasagiline and selegiline. Basal Ganglia. 2012. doi:10.1016/j.baga.2012.04.032
29. Journal / agency Rothman RB, Baumann MH. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol. October 2003. doi:10.1016/j.ejphar.2003.08.054 · PMID 14612135
30. Journal / agency Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit. April 2002. doi:10.1097/00007691-200204000-00009 · PMID 11897973
31. Journal / agency Parnham MJ. Inhibitors of Monoamine Oxidase B: Pharmacology and Clinical Use in Neurodegenerative Disorders. 1993. doi:10.1007/978-3-0348-6348-3_12
32. Journal / agency Tábi T, Vécsei L, Youdim MB, Riederer P, Szökő É. Selegiline: a molecule with innovative potential. J Neural Transm (Vienna). May 2020. doi:10.1007/s00702-019-02082-0 · PMID 31562557 · PMC7242272
33. Other Seaman J, Landry JT. Mylan: 50 Years of Unconventional Success: Making Quality Medicine Affordable and Accessible. 2011
34. Journal / agency Löhle M, Storch A. Orally disintegrating selegiline for the treatment of Parkinson's disease. Expert Opin Pharmacother. November 2008. doi:10.1517/14656566.9.16.2881 · PMID 18937619
35. Journal / agency Hoffman GR, Olson MG, Schoffstall AM, Estévez RF, Van den Eynde V, Gillman PK, Stabio ME. Classics in Chemical Neuroscience: Selegiline, Isocarboxazid, Phenelzine, and Tranylcypromine. ACS Chem Neurosci. December 2023. doi:10.1021/acschemneuro.3c00591 · PMID 37966854
36. Journal / agency Golbe LI. Deprenyl as symptomatic therapy in Parkinson's disease. Clin Neuropharmacol. October 1988. doi:10.1097/00002826-198810000-00001 · PMID 3146432
37. Journal / agency Schifano F, Catalani V, Sharif S, Napoletano F, Corkery JM, Arillotta D, Fergus S, Vento A, Guirguis A. Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals. Drugs. April 2022. doi:10.1007/s40265-022-01701-7 · PMID 35366192
38. Journal / agency Knoll J. Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain. CNS Drug Rev. 2001. doi:10.1111/j.1527-3458.2001.tb00202.x · PMID 11607046 · PMC6494119
39. Journal / agency Schneider LS, Tariot PN, Goldstein B. Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther. December 1994. doi:10.1038/clpt.1994.205 · PMID 7995017
40. Journal / agency Blazer DG, Yaffe K, Liverman CT. Risk and Protective Factors and Interventions: General Cognitive Aging Interventions and Next Steps. 21 July 2015
41. Journal / agency Brown RP, Gerbarg PL. Integrative Psychopharmacology: A Practical Approach to Herbs and Nutrients in Psychiatry. Review of Psychiatry. 2008
42. Journal / agency Finberg JP. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease. Journal of Neural Transmission. April 2019. doi:10.1007/s00702-018-1952-7 · PMID 30386930
43. Other Селегилин (Selegiline)
44. Journal / agency Drugs@FDA: FDA-Approved Drugs
45. Journal / agency Asnis GM, Henderson MA. EMSAM (deprenyl patch): how a promising antidepressant was underutilized. Neuropsychiatr Dis Treat. 2014. doi:10.2147/NDT.S59107 · PMID 25336957 · PMC4200016
46. Journal / agency Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Current Medicinal Chemistry. August 2004. doi:10.2174/0929867043364775 · PMID 15279566
47. Other Selegiline Hydrochloride Monograph for Professionals
48. Journal / agency Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, Gray R, Wheatley K. Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ. September 2004. doi:10.1136/bmj.38184.606169.AE · PMID 15310558 · PMC516655
49. Journal / agency Riederer P, Lachenmayer L. Selegiline's neuroprotective capacity revisited. Journal of Neural Transmission. November 2003. doi:10.1007/s00702-003-0083-x · PMID 14628191
50. Journal / agency Frisina PG, Tenenbaum HR, Borod JC, Foldi NS. The effects of antidepressants in Parkinson's disease: a meta-analysis. Int J Neurosci. May 2008. doi:10.1080/00207450701239418 · PMID 18446583
51. Journal / agency Tsuboi T, Satake Y, Hiraga K, Yokoi K, Hattori M, Suzuki M, Hara K, Ramirez-Zamora A, Okun MS, Katsuno M. Effects of MAO-B inhibitors on non-motor symptoms and quality of life in Parkinson's disease: A systematic review. npj Parkinson's Disease. June 2022. doi:10.1038/s41531-022-00339-2 · PMID 35697709 · PMC9192747
52. Journal / agency Binde CD, Tvete IF, Gåsemyr J, Natvig B, Klemp M. A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease. Br J Clin Pharmacol. September 2018. doi:10.1111/bcp.13651 · PMID 29847694 · PMC6089809
53. Journal / agency Hengartner MP, Jakobsen JC, Sørensen A, Plöderl M. Efficacy of new-generation antidepressants assessed with the Montgomery-Asberg Depression Rating Scale, the gold standard clinician rating scale: A meta-analysis of randomised placebo-controlled trials. PLOS ONE. 2020. doi:10.1371/journal.pone.0229381 · PMID 32101579 · PMC7043778
54. Journal / agency Cristancho MA, Thase ME. Critical appraisal of selegiline transdermal system for major depressive disorder. Expert Opinion on Drug Delivery. 2016. doi:10.1517/17425247.2016.1140145 · PMID 26837935
55. Journal / agency Pae CU, Patkar AA, Jang S, Portland KB, Jung S, Nelson JC. Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials. CNS Spectr. August 2014. doi:10.1017/S1092852913000655 · PMID 24168807
56. Journal / agency Clayton AH, Campbell BJ, Favit A, Yang Y, Moonsammy G, Piontek CM, Amsterdam JD. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale. J Clin Psychiatry. December 2007. doi:10.4088/jcp.v68n1205 · PMID 18162016
57. Journal / agency Winter J, Curtis K, Hu B, Clayton AH. Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management. Expert Opin Drug Saf. July 2022. doi:10.1080/14740338.2022.2049753 · PMID 35255754
58. Journal / agency Pae CU, Lim HK, Han C, Neena A, Lee C, Patkar AA. Selegiline transdermal system: current awareness and promise. Prog Neuropsychopharmacol Biol Psychiatry. August 2007. doi:10.1016/j.pnpbp.2007.04.020 · PMID 17614182
59. Other Knoll J. How Selegiline ((-)-Deprenyl) Slows Brain Aging. 2012
60. Journal / agency Healy D. The Psychopharmacologists, Vol. III: Interviews. 2000. doi:10.4324/9781003058892-3
61. Journal / agency Ferdinandy P, Yoneda F, Muraoka S, Fürst S, Gyires K, Miklya I. Geroprotection in the future. In memoriam of Joseph Knoll: The selegiline story continues. European Journal of Pharmacology. February 2020. doi:10.1016/j.ejphar.2019.172793 · PMID 31743738
62. Other Pearce D. The Hedonistic Imperative. 1995
63. Other Sam Barker and David Pearce on Art, Paradise Engineering, and Existential Hope (With Guest Mix) | The FLI Podcast. 2020-06-24
64. Other cite
65. Other Murphy HT. Sam Bankman-Fried Confirmed He Wears an Emsam Patch. What's an Emsam Patch?. 14 December 2022
66. Other Sigalos M. Sam Bankman-Fried wins approval to receive Adderall for ADHD while in jail. 14 August 2023
67. Other Alexander S. The Psychopharmacology Of The FTX Crash. 16 November 2022
68. Journal / agency Knoll J, Miklya I. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP). Life Sciences. December 2016. doi:10.1016/j.lfs.2016.10.023 · PMID 27777099
69. Other Furst S. In memoriam Joseph Knoll (1925-2018) | Hungarian Society for Experimental and Clinical Pharmacology. 2018
70. Journal / agency Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes. Update 2014. J Alzheimers Dis. 2014. doi:10.3233/JAD-140402 · PMID 24903780
71. Journal / agency Carageorgiou H, Sideris AC, Messari I, Liakou CI, Tsakiris S. The effects of rivastigmine plus selegiline on brain acetylcholinesterase, (Na, K)-, Mg-ATPase activities, antioxidant status, and learning performance of aged rats. Neuropsychiatric Disease and Treatment. August 2008. doi:10.2147/ndt.s3272 · PMID 19043511 · PMC2536534
72. Journal / agency Stoll S, Hafner U, Pohl O, Müller WE. Age-related memory decline and longevity under treatment with selegiline. Life Sciences. 1994. doi:10.1016/0024-3205(94)00396-3 · PMID 7997074
73. Journal / agency Puurunen K, Jolkkonen J, Sirviö J, Haapalinna A, Sivenius J. Selegiline combined with enriched-environment housing attenuates spatial learning deficits following focal cerebral ischemia in rats. Experimental Neurology. February 2001. doi:10.1006/exnr.2000.7563 · PMID 11161623
74. Journal / agency Knoll J. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view. Pharmacology & Toxicology. May 1992. doi:10.1111/j.1600-0773.1992.tb00480.x · PMID 1608919
75. Journal / agency Bruyette DS, Ruehl WW, Entriken T, Griffin D, Darling L. Management of canine pituitary-dependent hyperadrenocorticism with l-deprenyl (Anipryl). Vet Clin North Am Small Anim Pract. March 1997. doi:10.1016/s0195-5616(97)50031-3 · PMID 9076907
76. Other Braddock JA, Church DB, Robertson ID. Selegiline Treatment of Canine Pituitary-Dependent Hyperadrenocorticism. 2004
77. Other Eghianruwa K. Essential Drug Data for Rational Therapy in Veterinary Practice. 2014
78. Journal / agency Prpar Mihevc S, Majdič G. Canine Cognitive Dysfunction and Alzheimer's Disease - Two Facets of the Same Disease?. Front Neurosci. 2019. doi:10.3389/fnins.2019.00604 · PMID 31249505 · PMC6582309
79. Other Anipryl Tablets for Animal Use
80. Other Lundgren B. Canine Cognitive Dysfunction
81. Other Riviere JE, Papich MG. Veterinary Pharmacology and Therapeutics. 2013
82. Other Papich MG. Saunders Handbook of Veterinary Drugs: Small and Large Animal. 2015
83. Journal / agency Kalász H, Magyar K, Szőke É, Adeghate E, Adem A, Hasan MY, Nurulain SM, Tekes K. Metabolism of selegiline [(-)-deprenyl)]. Curr Med Chem. 2014. doi:10.2174/0929867321666131218094352 · PMID 24350849
84. Journal / agency Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl. 1983. doi:10.1111/j.1600-0404.1983.tb01517.x · PMID 6428148
85. Journal / agency Alborghetti M, Nicoletti F. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside. Curr Neuropharmacol. 2019. doi:10.2174/1570159X16666180830100754 · PMID 30160213 · PMC7052841
86. Journal / agency Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. The New England Journal of Medicine. June 2007. doi:10.1056/NEJMp078015 · PMID 17485726
87. Journal / agency Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. May 2006. doi:10.1017/s1092852900014498 · PMID 16641841
88. Journal / agency Finberg JP, Gillman K. Monoamine Oxidase and their Inhibitors. 2011. doi:10.1016/B978-0-12-386467-3.00009-1 · PMID 21971008
89. Journal / agency Olanow CW, Myllylä VV, Sotaniemi KA, Larsen JP, Pålhagen S, Przuntek H, Heinonen EH, Kilkku O, Lammintausta R, Mäki-Ikola O, Rinne UK. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology. September 1998. doi:10.1212/wnl.51.3.825 · PMID 9748034
90. Journal / agency Aaltonen H, Kilkku O, Heinonen E, Mäki-Ikola O. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality. BMJ. December 1998. doi:10.1136/bmj.317.7172.1586 · PMID 9890764 · PMC1114394
91. Journal / agency Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol. October 2004. doi:10.1038/sj.bjp.0705962 · PMID 15339864 · PMC1575354
92. Journal / agency Roy MA, Doiron M, Talon-Croteau J, Dupré N, Simard M. Effects of Antiparkinson Medication on Cognition in Parkinson's Disease: A Systematic Review. Can J Neurol Sci. July 2018. doi:10.1017/cjn.2018.21 · PMID 29747716
93. Journal / agency Vitale C, Amboni M, Erro R, Picillo M, Pellecchia MT, Barone P, Trojano L, Santangelo G. Parkinson's disease management and impulse control disorders: current state and future perspectives. Expert Rev Neurother. June 2019. doi:10.1080/14737175.2019.1620603 · PMID 31148487
94. Journal / agency Djamshidian A, Cardoso F, Grosset D, Bowden-Jones H, Lees AJ. Pathological gambling in Parkinson's disease--a review of the literature. Mov Disord. September 2011. doi:10.1002/mds.23821 · PMID 21661054
95. Journal / agency Drapier D, Drapier S, Sauleau P, Derkinderen P, Damier P, Allain H, Vérin M, Millet B. Pathological gambling secondary to dopaminergic therapy in Parkinson's disease. Psychiatry Res. November 2006. doi:10.1016/j.psychres.2006.04.017 · PMID 17011634
96. Journal / agency Solla P, Bortolato M, Cannas A, Mulas CS, Marrosu F. Paraphilias and paraphilic disorders in Parkinson's disease: A systematic review of the literature. Mov Disord. April 2015. doi:10.1002/mds.26157 · PMID 25759330 · PMC4428164
97. Journal / agency Hirao K, Kaneko Y, Hirose D, Fukasawa R, Shimizu S, Kanetaka H, Umahara T, Sakurai H, Hanyu H. Patient with Parkinson's disease presenting with impulse control disorders following treatment with selegiline. Int Psychogeriatr. September 2019. doi:10.1017/S1041610218001862 · PMID 30520410
98. Journal / agency Uitti RJ, Tanner CM, Rajput AH, Goetz CG, Klawans HL, Thiessen B. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol. October 1989. doi:10.1097/00002826-198910000-00002 · PMID 2575449
99. Journal / agency Riley DE. Reversible transvestic fetishism in a man with Parkinson's disease treated with selegiline. Clin Neuropharmacol. 2002. doi:10.1097/00002826-200207000-00008 · PMID 12151912
100. Journal / agency Shapiro MA, Chang YL, Munson SK, Okun MS, Fernandez HH. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases. Parkinsonism Relat Disord. September 2006. doi:10.1016/j.parkreldis.2006.01.010 · PMID 16730214
101. Journal / agency Seeman P. Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. April 2015. doi:10.1002/syn.21805 · PMID 25645960
102. Journal / agency Garcia-Ruiz PJ. Impulse Control Disorders and Dopamine-Related Creativity: Pathogenesis and Mechanism, Short Review, and Hypothesis. Front Neurol. 2018. doi:10.3389/fneur.2018.01041 · PMID 30574117 · PMC6291460
103. Journal / agency Williams BD, Lee K, Ewah SO, Neelam K. Aripiprazole and Other Third-Generation Antipsychotics as a Risk Factor for Impulse Control Disorders: A Systematic Review and Meta-Analysis. J Clin Psychopharmacol. 2024. doi:10.1097/JCP.0000000000001773 · PMID 38011021
104. Journal / agency Kubota H, Zhou X, Zhang X, Watanabe H, Nagai T. Pramipexole Hyperactivates the External Globus Pallidus and Impairs Decision-Making in a Mouse Model of Parkinson's Disease. Int J Mol Sci. August 2024. doi:10.3390/ijms25168849 · PMID 39201535 · PMC11354263
105. Journal / agency Howell M, Avidan AY, Foldvary-Schaefer N, Malkani RG, During EH, Roland JP, McCarter SJ, Zak RS, Carandang G, Kazmi U, Ramar K. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. April 2023. doi:10.5664/jcsm.10424 · PMID 36515157 · PMC10071384
106. Journal / agency Hoque R, Chesson AL. Pharmacologically induced/exacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorder/REM sleep without atonia: literature review, qualitative scoring, and comparative analysis. J Clin Sleep Med. February 2010. doi:10.5664/jcsm.27716 · PMID 20191944 · PMC2823282
107. Journal / agency Louden MB, Morehead MA, Schmidt HS. Activation by selegiline (Eldepryle) of REM sleep behavior disorder in parkinsonism. W V Med J. 1995. PMID 7747490
108. Journal / agency Goldberg SR, Yasar S, Bergman J, Youdim MB. Introduction: examination of clinical and preclinical pharmacologic data relating to abuse liability of l-deprenyl (selegiline). Clin Pharmacol Ther. December 1994. doi:10.1038/clpt.1994.201 · PMID 7995013
109. Journal / agency Winger GD, Yasar S, Negus SS, Goldberg SR. Intravenous self-administration studies with l-deprenyl (selegiline) in monkeys. Clin Pharmacol Ther. December 1994. doi:10.1038/clpt.1994.208 · PMID 7995020
110. Journal / agency Yasar S, Gaál J, Panlilio LV, Justinova Z, Molnár SV, Redhi GH, Schindler CW. A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys. Psychopharmacology (Berl). January 2006. doi:10.1007/s00213-005-0200-7 · PMID 16292593 · PMC1360227
111. Journal / agency McKean AJ, Leung JG, Dare FY, Sola CL, Schak KM. The Perils of Illegitimate Online Pharmacies: Substance-Induced Panic Attacks and Mood Instability Associated With Selegiline and Phenylethylamine. Psychosomatics. 2015. doi:10.1016/j.psym.2015.05.003 · PMID 26198572
112. Journal / agency Monteith S, Glenn T, Bauer R, Conell J, Bauer M. Availability of prescription drugs for bipolar disorder at online pharmacies. J Affect Disord. March 2016. doi:10.1016/j.jad.2015.12.043 · PMID 26766033
113. Journal / agency Kuhn W, Müller T. The clinical potential of Deprenyl in neurologic and psychiatric disorders. Journal of Neural Transmission. Supplementum. 1996. doi:10.1007/978-3-7091-7494-4_8 · PMID 8988464
114. Journal / agency Deng X, Shang X, Guo K, Zhou L, Wang Y, Wu Y, Liang S, E F, Liu W, Wang Z, Li X, Yang K. Efficacy and safety of antidepressants for smoking cessation: A systematic review and network meta-analysis. Addict Biol. August 2023. doi:10.1111/adb.13303 · PMID 37500482
115. Journal / agency Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. May 2023. doi:10.1002/14651858.CD000031.pub6 · PMID 37230961 · PMC10207863
116. Journal / agency Castells X, Casas M, Pérez-Mañá C, Roncero C, Vidal X, Capellà D. Efficacy of psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. February 2010. doi:10.1002/14651858.CD007380.pub3 · PMID 20166094
117. Journal / agency Finberg JP. Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. Pharmacol Ther. August 2014. doi:10.1016/j.pharmthera.2014.02.010 · PMID 24607445
118. Journal / agency Houtsmuller EJ, Notes LD, Newton T, van Sluis N, Chiang N, Elkashef A, Bigelow GE. Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (Berl). February 2004. doi:10.1007/s00213-003-1616-6 · PMID 14605792
119. Journal / agency Bartzokis G, Beckson M, Newton T, Mandelkern M, Mintz J, Foster JA, Ling W, Bridge TP. Selegiline effects on cocaine-induced changes in medial temporal lobe metabolism and subjective ratings of euphoria. Neuropsychopharmacology. June 1999. doi:10.1016/S0893-133X(98)00092-X · PMID 10327427
120. Journal / agency Haberny KA, Walsh SL, Ginn DH, Wilkins JN, Garner JE, Setoda D, Bigelow GE. Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend. July 1995. doi:10.1016/0376-8716(95)01137-n · PMID 7587975
121. Journal / agency Harris DS, Everhart T, Jacob P, Lin E, Mendelson JE, Jones RT. A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion. BMC Clin Pharmacol. August 2009. doi:10.1186/1472-6904-9-13 · PMID 19646280 · PMC2731040
122. Journal / agency Newton TF, Kalechstein A, Beckson M, Bartzokis G, Bridge TP, Ling W. Effects of selegiline pretreatment on response to experimental cocaine administration. Psychiatry Res. October 1999. doi:10.1016/s0165-1781(99)00058-x · PMID 10579543
123. Journal / agency Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J. Pharmacotherapy of methamphetamine addiction: an update. Subst Abus. 2008. doi:10.1080/08897070802218554 · PMID 19042205 · PMC2597382
124. Journal / agency Newton TF, De La Garza R, Fong T, Chiang N, Holmes TH, Bloch DA, Anderson A, Elkashef A. A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline. Pharmacol Biochem Behav. December 2005. doi:10.1016/j.pbb.2005.11.012 · PMID 16413604
125. Journal / agency Knoll J. The pharmacology of selegiline ((-)deprenyl). New aspects. Acta Neurologica Scandinavica. Supplementum. 1989. doi:10.1111/j.1600-0404.1989.tb01787.x · PMID 2515725
126. Journal / agency Ebadi M, Sharma S, Shavali S, El Refaey H. Neuroprotective actions of selegiline. Journal of Neuroscience Research. February 2002. doi:10.1002/jnr.10148 · PMID 11813232
127. Journal / agency Bentué-Ferrer D, Ménard G, Allain H. Monoamine Oxidase B Inhibitors: Current Status and Future Potential. CNS Drugs. 1996. doi:10.2165/00023210-199606030-00005
128. Journal / agency Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson's disease. Journal of Neural Transmission. 1978. doi:10.1007/BF01246955 · PMID 745011
129. Journal / agency Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. European Journal of Pharmacology. October 1984. doi:10.1016/0014-2999(84)90700-3 · PMID 6442232
130. Journal / agency Finnegan KT, DeLanney LE, Irwin I, Ricaurte GA, Langston JW. The amine-depleting effects of 5,7-dihydroxytryptamine (5,7-DHT) in C57BL/6 mice do not increase with age. Brain Research. September 1989. doi:10.1016/0006-8993(89)91072-x · PMID 2804634
131. Journal / agency Moratalla R, Khairnar A, Simola N, Granado N, García-Montes JR, Porceddu PF, Tizabi Y, Costa G, Morelli M. Amphetamine-related drugs neurotoxicity in humans and in experimental animals: Main mechanisms. Prog Neurobiol. August 2017. doi:10.1016/j.pneurobio.2015.09.011 · PMID 26455459
132. Journal / agency Puerta E, Aguirre N. Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation. Pharmaceuticals. 5 July 2011. doi:10.3390/ph4070992 · PMC4058674
133. Journal / agency Sprague JE, Nichols DE. Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. Psychopharmacology. April 1995. doi:10.1007/BF02245967 · PMID 7542394
134. Journal / agency Sprague JE, Nichols DE. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J Pharmacol Exp Ther. May 1995. doi:10.1016/S0022-3565(25)09490-X · PMID 7538579
135. Journal / agency Alves E, Summavielle T, Alves CJ, Gomes-da-Silva J, Barata JC, Fernandes E, Bastos Mde L, Tavares MA, Carvalho F. Monoamine oxidase-B mediates ecstasy-induced neurotoxic effects to adolescent rat brain mitochondria. J Neurosci. September 2007. doi:10.1523/JNEUROSCI.2645-07.2007 · PMID 17881526 · PMC6672671
136. Journal / agency Corkery JM, Elliott S, Schifano F, Corazza O, Ghodse AH. MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f] [1,3]benzodioxol-6-amine; 'sparkle'; 'mindy') toxicity: a brief overview and update. Hum Psychopharmacol. July 2013. doi:10.1002/hup.2298 · PMID 23881883
137. Journal / agency Johnson MP, Huang XM, Nichols DE. Serotonin neurotoxicity in rats after combined treatment with a dopaminergic agent followed by a nonneurotoxic 3,4-methylenedioxymethamphetamine (MDMA) analogue. Pharmacol Biochem Behav. December 1991. doi:10.1016/0091-3057(91)90106-c · PMID 1726189
138. Journal / agency Halladay AK, Kirschner E, Hesse K, Fisher H, Wagner GC. Role of monoamine oxidase inhibition and monoamine depletion in fenfluramine-induced neurotoxicity and serotonin release. Pharmacol Toxicol. November 2001. doi:10.1034/j.1600-0773.2001.d01-154.x · PMID 11881977
139. Journal / agency Benmansour S, Brunswick DJ. The MAO-B inhibitor deprenyl, but not the MAO-A inhibitor clorgyline, potentiates the neurotoxicity of p-chloroamphetamine. Brain Res. July 1994. doi:10.1016/0006-8993(94)91796-5 · PMID 7953696
140. Journal / agency Sprague JE, Johnson MP, Schmidt CJ, Nichols DE. Studies on the mechanism of p-chloroamphetamine neurotoxicity. Biochem Pharmacol. October 1996. doi:10.1016/0006-2952(96)00482-0 · PMID 8937435
141. Journal / agency Goldberg SR, Yasar S. Neurochemistry: Cellular, Molecular, and Clinical Aspects. 1997. doi:10.1007/978-1-4615-5405-9_55
142. Journal / agency Wan FJ, Shiah IS, Lin HC, Huang SY, Tung CS. Nomifensine attenuates d-amphetamine-induced dopamine terminal neurotoxicity in the striatum of rats. Chin J Physiol. June 2000. PMID 10994696
143. Journal / agency Grasing K, Azevedo R, Karuppan S, Ghosh S. Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion. Neurochem Res. January 2001. doi:10.1023/a:1007632700126 · PMID 11358284
144. Journal / agency Davidson C, Chen Q, Zhang X, Xiong X, Lazarus C, Lee TH, Ellinwood EH. Deprenyl treatment attenuates long-term pre- and post-synaptic changes evoked by chronic methamphetamine. Eur J Pharmacol. November 2007. doi:10.1016/j.ejphar.2007.06.046 · PMID 17651730
145. Journal / agency Carvalho M, Carmo H, Costa VM, Capela JP, Pontes H, Remião F, Carvalho F, Bastos Mde L. Toxicity of amphetamines: an update. Arch Toxicol. August 2012. doi:10.1007/s00204-012-0815-5 · PMID 22392347
146. Journal / agency Edinoff AN, Swinford CR, Odisho AS, Burroughs CR, Stark CW, Raslan WA, Cornett EM, Kaye AM, Kaye AD. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. Health Psychol Res. 2022. doi:10.52965/001c.39576 · PMID 36425231 · PMC9680847
147. Journal / agency Heinonen EH, Myllylä V. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Safety. July 1998. doi:10.2165/00002018-199819010-00002 · PMID 9673855
148. Journal / agency Csoti I, Storch A, Müller W, Jost WH. Drug interactions with selegiline versus rasagiline. Basal Ganglia. December 1, 2012. doi:10.1016/j.baga.2012.06.003
149. Journal / agency Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. British Journal of Anaesthesia. October 2005. doi:10.1093/bja/aei210 · PMID 16051647
150. Journal / agency Jessen L, Kovalick LJ, Azzaro AJ. The selegiline transdermal system (emsam): a therapeutic option for the treatment of major depressive disorder. P & T. April 2008. PMID 19750165 · PMC2730099
151. Journal / agency Azzaro AJ, VanDenBerg CM, Ziemniak J, Kemper EM, Blob LF, Campbell BJ. Evaluation of the potential for pharmacodynamic and pharmacokinetic drug interactions between selegiline transdermal system and two sympathomimetic agents (pseudoephedrine and phenylpropanolamine) in healthy volunteers. J Clin Pharmacol. August 2007. doi:10.1177/0091270007302950 · PMID 17554106
152. Journal / agency Feinberg SS. Combining stimulants with monoamine oxidase inhibitors: a review of uses and one possible additional indication. J Clin Psychiatry. November 2004. doi:10.4088/jcp.v65n1113 · PMID 15554766
153. Journal / agency Thomas SJ, Shin M, McInnis MG, Bostwick JR. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression. Pharmacotherapy. April 2015. doi:10.1002/phar.1576 · PMID 25884531
154. Journal / agency Israel JA. Combining Stimulants and Monoamine Oxidase Inhibitors: A Reexamination of the Literature and a Report of a New Treatment Combination. Prim Care Companion CNS Disord. 2015. doi:10.4088/PCC.15br01836 · PMID 27057401 · PMC4805402
155. Journal / agency Culpepper L, Kovalick LJ. A review of the literature on the selegiline transdermal system: an effective and well-tolerated monoamine oxidase inhibitor for the treatment of depression. Prim Care Companion J Clin Psychiatry. 2008. doi:10.4088/pcc.v10n0105 · PMID 18311418 · PMC2249821
156. Journal / agency Eccles R. Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse. Br J Clin Pharmacol. January 2007. doi:10.1111/j.1365-2125.2006.02833.x · PMID 17116124 · PMC2000711
157. Journal / agency Richards E, Lopez MJ, Maani CV. StatPearls. 2023. PMID 30521222
158. Journal / agency Schachter M. Side Effects of Drugs Annual. 2002. doi:10.1016/s0378-6080(02)80020-4
159. Journal / agency Rose LM, Ohlinger MJ, Mauro VF. A hypertensive reaction induced by concurrent use of selegiline and dopamine. Ann Pharmacother. September 2000. doi:10.1345/aph.19221 · PMID 10981248
160. Journal / agency Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. February 2011. doi:10.1097/JCP.0b013e31820469ea · PMID 21192146
161. Journal / agency Gillman PK. A reassessment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. J Neural Transm (Vienna). November 2018. doi:10.1007/s00702-018-1932-y · PMID 30255284
162. Journal / agency Van den Eynde V, Godet L, Redhead C, Horwitz A, Barnett B. Monoamine Oxidase Inhibitors and Clinically Relevant Drug Interactions: A Guide for Preventing Serotonin Toxicity and Hypertensive Reactions. Psychiatric Annals. 2023. doi:10.3928/00485713-20230713-02
163. Journal / agency Van den Eynde V, Abdelmoemin WR, Abraham MM, Amsterdam JD, Anderson IM, Andrade C, Baker GB, Beekman AT, Berk M, Birkenhäger TK, Blackwell BB, Blier P, Blom MB, Bodkin AJ, Cattaneo CI, Dantz B, Davidson J, Dunlop BW, Estévez RF, Feinberg SS, Finberg JP, Fochtmann LJ, Gotlib D, Holt A, Insel TR, Larsen JK, Mago R, Menkes DB, Meyer JM, Nutt DJ, Parker G, Rego MD, Richelson E, Ruhé HG, Sáiz-Ruiz J, Stahl SM, Steele T, Thase ME, Ulrich S, van Balkom AJ, Vieta E, Whyte I, Young AH, Gillman PK. The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS Spectr. July 2022. doi:10.1017/S1092852922000906 · PMID 35837681
164. Journal / agency Halman A, Kong G, Sarris J, Perkins D. Drug-drug interactions involving classic psychedelics: A systematic review. J Psychopharmacol. January 2024. doi:10.1177/02698811231211219 · PMID 37982394 · PMC10851641
165. Journal / agency Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. 2C or not 2C: phenethylamine designer drug review. J Med Toxicol. June 2013. doi:10.1007/s13181-013-0295-x · PMID 23494844 · PMC3657019
166. Journal / agency Theobald DS, Maurer HH. Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). Biochem Pharmacol. January 2007. doi:10.1016/j.bcp.2006.09.022 · PMID 17067556
167. Journal / agency Rodrigues AD. Drug Interactions Involving 17α-Ethinylestradiol: Considerations Beyond Cytochrome P450 3A Induction and Inhibition. Clin Pharmacol Ther. June 2022. doi:10.1002/cpt.2383 · PMID 34342002
168. Journal / agency Scheinin H, Anttila M, Dahl ML, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L. CYP2D6 polymorphism is not crucial for the disposition of selegiline. Clin Pharmacol Ther. October 1998. doi:10.1016/S0009-9236(98)90071-6 · PMID 9797797
169. Journal / agency Laine K, Anttila M, Nyman L, Wahlberg A, Bertilsson L. CYP2C19 polymorphism is not important for the in vivo metabolism of selegiline. Eur J Clin Pharmacol. May 2001. doi:10.1007/s002280100289 · PMID 11417445
170. Journal / agency Kivistö KT, Wang JS, Backman JT, Nyman L, Taavitsainen P, Anttila M, Neuvonen PJ. Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. Eur J Clin Pharmacol. April 2001. doi:10.1007/s002280100278 · PMID 11372588
171. Journal / agency Table of Substrates, Inhibitors and Inducers. 5 June 2023
172. Journal / agency Hidestrand M, Oscarson M, Salonen JS, Nyman L, Pelkonen O, Turpeinen M, Ingelman-Sundberg M. CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes. Drug Metab Dispos. November 2001. PMID 11602525
173. Journal / agency Naoi M, Maruyama W, Shamoto-Nagai M. Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies. Int J Mol Sci. September 2022. doi:10.3390/ijms231911059 · PMID 36232361 · PMC9570229
174. Journal / agency Klietz M, Greten S, Wegner F, Höglinger GU. Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients. Drugs & Aging. June 2019. doi:10.1007/s40266-019-00654-z · PMID 30937878
175. Journal / agency Laine K, Anttila M, Helminen A, Karnani H, Huupponen R. Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids. Br J Clin Pharmacol. March 1999. doi:10.1046/j.1365-2125.1999.00891.x · PMID 10215747 · PMC2014223
176. Journal / agency Palovaara S, Anttila M, Nyman L, Laine K. Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline. European Journal of Clinical Pharmacology. July 2002. doi:10.1007/s00228-002-0469-y · PMID 12136372
177. Journal / agency Anttila M, Sotaniemi EA, Pelkonen O, Rautio A. Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin Pharmacol Ther. January 2005. doi:10.1016/j.clpt.2004.09.004 · PMID 15637531
178. Journal / agency Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013. doi:10.3389/fgene.2013.00024 · PMID 23467454 · PMC3588594
179. Journal / agency Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. September 2016. doi:10.1016/j.apsb.2016.07.016 · PMID 27709010 · PMC5045548
180. Journal / agency Sridar C, Kenaan C, Hollenberg PF. Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. Drug Metab Dispos. December 2012. doi:10.1124/dmd.112.046979 · PMID 22936314 · PMC3500550
181. Journal / agency Nirogi R, Palacharla RC, Mohammed AR, Manoharan A, Ponnamaneni RK, Bhyrapuneni G. Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction. Chem Biol Interact. March 2015. doi:10.1016/j.cbi.2015.01.028 · PMID 25656918
182. Journal / agency Ritter JL, Alexander B. Retrospective study of selegiline-antidepressant drug interactions and a review of the literature. Ann Clin Psychiatry. March 1997. doi:10.1023/a:1026222106851 · PMID 9167831
183. Journal / agency Tanner JA, Tyndale RF. Variation in CYP2A6 Activity and Personalized Medicine. J Pers Med. December 2017. doi:10.3390/jpm7040018 · PMID 29194389 · PMC5748630
184. Journal / agency Siu EC, Tyndale RF. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther. March 2008. doi:10.1124/jpet.107.133900 · PMID 18065502
185. Journal / agency Laine K, Anttila M, Huupponen R, Mäki-Ikola O, Heinonen E. Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding. Clin Neuropharmacol. 2000. doi:10.1097/00002826-200001000-00005 · PMID 10682227
186. Journal / agency Pfeiffer RF. Antiparkinsonian agents. Drug interactions of clinical significance. Drug Saf. May 1996. doi:10.2165/00002018-199614050-00006 · PMID 8800629
187. Other Deprenyl | MedChemExpress (MCE) Life Science Reagents
188. Journal / agency Gaszner P, Miklya I. The use of the synthetic enhancer substances (-)-deprenyl and (-)-BPAP in major depression. Neuropsychopharmacol Hung. December 2004. PMID 15825677
189. Journal / agency Knoll J. Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives. Neurochem Res. August 2003. doi:10.1023/a:1024224311289 · PMID 12834268
190. Journal / agency Knoll J. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes. Biomed Pharmacother. 1995. doi:10.1016/0753-3322(96)82619-9 · PMID 7669938
191. Journal / agency Knoll J. Memories of my 45 years in research. Pharmacol Toxicol. August 1994. doi:10.1111/j.1600-0773.1994.tb00326.x · PMID 7971740
192. Journal / agency Goldstein DS, Kopin IJ, Sharabi Y. Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders. Pharmacol Ther. December 2014. doi:10.1016/j.pharmthera.2014.06.006 · PMID 24945828 · PMC4591072
193. Journal / agency Goldstein DS. The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know. Int J Mol Sci. June 2021. doi:10.3390/ijms22115999 · PMID 34206133 · PMC8199574
194. Journal / agency Goldstein DS. The catecholaldehyde hypothesis: where MAO fits in. J Neural Transm (Vienna). February 2020. doi:10.1007/s00702-019-02106-9 · PMID 31807952 · PMC10680281
195. Journal / agency Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykkö KA, Lammintausta RA. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans. J Clin Pharmacol. July 1997. doi:10.1002/j.1552-4604.1997.tb04342.x · PMID 9243353
196. Journal / agency Miklya I. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline. Pharmacol Rep. June 2014. doi:10.1016/j.pharep.2013.11.003 · PMID 24905523
197. Journal / agency Miklya I. (-)-deprenil, az N-metilprogargilamin-1-aminoindan (J-508) és a J-508 dezmetil analógjának (rasagilin) összehasonlító farmakológiai analízise. Neuropsychopharmacol Hung. March 2008. PMID 18771016
198. Journal / agency Clarke A, Brewer F, Johnson ES, Mallard N, Hartig F, Taylor S, Corn TH. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. Journal of Neural Transmission. November 2003. doi:10.1007/s00702-003-0036-4 · PMID 14628189
199. Journal / agency Heinonen EH, Anttila MI, Lammintausta RA. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. December 1994. doi:10.1038/clpt.1994.204 · PMID 7995016
200. Journal / agency Heinonen EH, Myllylä V, Sotaniemi K, Lamintausta R, Salonen JS, Anttila M, Savijärvi M, Kotila M, Rinne UK. Pharmacokinetics and metabolism of selegiline. Acta Neurologica Scandinavica. Supplementum. November 1989. doi:10.1111/j.1600-0404.1989.tb01788.x · PMID 2515726
201. Journal / agency Chrisp P, Mammen GJ, Sorkin EM. Selegiline: A Review of its Pharmacology, Symptomatic Benefits and Protective Potential in Parkinson's Disease. Drugs Aging. May 1991. doi:10.2165/00002512-199101030-00006 · PMID 1794016
202. Journal / agency Velenosi TJ, Urquhart BL. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol. August 2014. doi:10.1517/17425255.2014.931371 · PMID 24961255
203. Journal / agency Baghdady NT, Banik S, Swartz SA, McIntyre RS. Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther. April 2009. doi:10.1007/s12325-009-0021-x · PMID 19444657
204. Journal / agency Janssen PA, Leysen JE, Megens AA, Awouters FH. Does phenylethylamine act as an endogenous amphetamine in some patients?. Int J Neuropsychopharmacol. September 1999. doi:10.1017/S1461145799001522 · PMID 11281991
205. Journal / agency Birkmayer W, Riederer P, Linauer W, Knoll J. L-deprenyl plus L-phenylalanine in the treatment of depression. J Neural Transm. 1984. doi:10.1007/BF01249880 · PMID 6425455
206. Journal / agency Sabelli HC. Rapid treatment of depression with selegiline-phenylalanine combination. J Clin Psychiatry. March 1991. PMID 1900832
207. Journal / agency Sabelli H, Fink P, Fawcett J, Tom C. Sustained antidepressant effect of PEA replacement. J Neuropsychiatry Clin Neurosci. 1996. doi:10.1176/jnp.8.2.168 · PMID 9081552
208. Journal / agency Simpson HB, Schneier FR, Marshall RD, Campeas RB, Vermes D, Silvestre J, Davies S, Liebowitz MR. Low dose selegiline (L-Deprenyl) in social phobia. Depress Anxiety. 1998. doi:10.1002/(SICI)1520-6394(1998)7:3<126::AID-DA5>3.0.CO;2-9 · PMID 9656093
209. Journal / agency Padilha SC, Virtuoso S, Tonin FS, Borba HH, Pontarolo R. Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. European Child & Adolescent Psychiatry. October 2018. doi:10.1007/s00787-018-1125-0 · PMID 29460165
210. Journal / agency Buoli M, Serati M, Cahn W. Alternative pharmacological strategies for adult ADHD treatment: a systematic review. Expert Review of Neurotherapeutics. 2016. doi:10.1586/14737175.2016.1135735 · PMID 26693882
211. Journal / agency Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. September 2009. doi:10.1097/CHI.0b013e3181b26e9f · PMID 19625978 · PMC3943246
212. Journal / agency Rubinstein S, Malone MA, Roberts W, Logan WJ. Placebo-controlled study examining effects of selegiline in children with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology. August 2006. doi:10.1089/cap.2006.16.404 · PMID 16958566
213. Journal / agency Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, Arabgol F, Amini H. Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Progress in Neuro-Psychopharmacology & Biological Psychiatry. August 2003. doi:10.1016/S0278-5846(03)00117-9 · PMID 12921918
214. Journal / agency Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. Journal of Attention Disorders. March 2002. doi:10.1177/108705470100500401 · PMID 11967475
215. Journal / agency Tcheremissine OV, Salazar JO. Pharmacotherapy of adult attention deficit/hyperactivity disorder: review of evidence-based practices and future directions. Expert Opinion on Pharmacotherapy. June 2008. doi:10.1517/14656566.9.8.1299 · PMID 18473705
216. Other Mechcatie E. Transdermal MAO inhibitor patch effective for ADHD. July 2003
217. Journal / agency Hailwood JM. Novel approaches towards pharmacological enhancement of motivation. 27 September 2018. doi:10.17863/CAM.40216
218. Journal / agency Callaghan CK, Rouine J, O'Mara SM. The Opioid System as the Interface between the Brain's Cognitive and Motivational Systems. 2018. doi:10.1016/bs.pbr.2018.07.009 · PMID 30314570
219. Journal / agency Yohn SE, Reynolds S, Tripodi G, Correa M, Salamone JD. The monoamine-oxidase B inhibitor deprenyl increases selection of high-effort activity in rats tested on a progressive ratio/chow feeding choice procedure: Implications for treating motivational dysfunctions. Behav Brain Res. April 2018. doi:10.1016/j.bbr.2017.12.039 · PMID 29292157
220. Journal / agency Contreras-Mora H, Rowland MA, Yohn SE, Correa M, Salamone JD. Partial reversal of the effort-related motivational effects of tetrabenazine with the MAO-B inhibitor deprenyl (selegiline): Implications for treating motivational dysfunctions. Pharmacol Biochem Behav. March 2018. doi:10.1016/j.pbb.2018.01.001 · PMID 29309800
221. Journal / agency van Dalen JW, Moll van Charante EP, Nederkoorn PJ, van Gool WA, Richard E. Poststroke apathy. Stroke. March 2013. doi:10.1161/STROKEAHA.112.674614 · PMID 23362076
222. Other Al-Adawi SH. The neuropsychopharmacology of motivation: an examination of reward and frontal-subcortical mechanisms and functions. 1998
223. Journal / agency Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B. Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci. 1995. doi:10.1176/jnp.7.1.23 · PMID 7711487
224. Journal / agency Newburn G, Newburn D. Selegiline in the management of apathy following traumatic brain injury. Brain Inj. February 2005. doi:10.1080/02699050410001719989 · PMID 15841758
225. Journal / agency Moutaouakil F, El Otmani H, Fadel H, Slassi I. Apathie sévère après un traumatisme crânien: évolution favorable sous Sélégiline. Neurochirurgie. December 2009. doi:10.1016/j.neuchi.2008.10.009 · PMID 19084243
226. Journal / agency Marin RS, Wilkosz PA. Disorders of diminished motivation. J Head Trauma Rehabil. 2005. doi:10.1097/00001199-200507000-00009 · PMID 16030444
227. Journal / agency Costa AM, Lima MS, Mari Jde J. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med J. September 2006. doi:10.1590/s1516-31802006000500012 · PMID 17262163 · PMC11068300
228. Journal / agency Schmidt HM, Hagen M, Kriston L, Soares-Weiser K, Maayan N, Berner MM. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev. November 2012. doi:10.1002/14651858.CD003546.pub3 · PMID 23152218 · PMC7003677
229. Journal / agency Murphy BP, Chung YC, Park TW, McGorry PD. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res. December 2006. doi:10.1016/j.schres.2006.07.002 · PMID 16930948
230. Journal / agency Maski K, Trotti LM, Kotagal S, Robert Auger R, Swick TJ, Rowley JA, Hashmi SD, Watson NF. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. September 2021. doi:10.5664/jcsm.9326 · PMID 34743790 · PMC8636345
231. Journal / agency Nishino S, Kotorii N. Narcolepsy: A Clinical Guide. 2016. doi:10.1007/978-3-319-23739-8_22
232. Journal / agency Nishino S, Arrigoni J, Kanbayashi T, Dement WC, Mignot E. Comparative effects of MAO-A and MAO-B selective inhibitors on canine cataplexy. Sleep Res. 1996
233. Journal / agency Annane D, Laberge L, Gallais B, Chevret S. Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy. The Cochrane Database of Systematic Reviews. November 2024. doi:10.1002/14651858.CD003218.pub3 · PMID 39555632 · PMC11571272
234. Journal / agency Yeh PG, Spruyt K, DelRosso LM, Walters AS. A Narrative Review of the Lesser Known Medications for Treatment of Restless Legs Syndrome and Pathogenetic Implications for Their Use. Tremor Other Hyperkinet Mov (N Y). 2023. doi:10.5334/tohm.739 · PMID 36873914 · PMC9983500
235. Journal / agency Aurora RN, Kristo DA, Bista SR, Rowley JA, Zak RS, Casey KR, Lamm CI, Tracy SL, Rosenberg RS. The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. August 2012. doi:10.5665/sleep.1988 · PMID 22851801 · PMC3397811
236. Journal / agency Grewal M, Hawa R, Shapiro C. Treatment of periodic limb movements in sleep with selegiline HCl. Mov Disord. March 2002. doi:10.1002/mds.10082 · PMID 11921131
237. Journal / agency Soares-Weiser K, Rathbone J, Ogawa Y, Shinohara K, Bergman H. Miscellaneous treatments for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. March 2018. doi:10.1002/14651858.CD000208.pub2 · PMID 29552749 · PMC6494382
238. Journal / agency Wilcock GK, Birks J, Whitehead A, Evans SJ. The effect of selegiline in the treatment of people with Alzheimer's disease: a meta-analysis of published trials. Int J Geriatr Psychiatry. February 2002. doi:10.1002/gps.545 · PMID 11813282
239. Journal / agency Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev. 2003. doi:10.1002/14651858.CD000442 · PMID 12535396
240. Journal / agency Sanders O, Rajagopal L. Phosphodiesterase Inhibitors for Alzheimer's Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale. J Alzheimers Dis Rep. June 2020. doi:10.3233/ADR-200191 · PMID 32715279 · PMC7369141
241. Journal / agency Laver K, Dyer S, Whitehead C, Clemson L, Crotty M. Interventions to delay functional decline in people with dementia: a systematic review of systematic reviews. BMJ Open. April 2016. doi:10.1136/bmjopen-2015-010767 · PMID 27121704 · PMC4854009
242. Journal / agency Stinton C, McKeith I, Taylor JP, Lafortune L, Mioshi E, Mak E, Cambridge V, Mason J, Thomas A, O'Brien JT. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry. August 2015. doi:10.1176/appi.ajp.2015.14121582 · PMID 26085043
243. Journal / agency Beghi E, Binder H, Birle C, Bornstein N, Diserens K, Groppa S, Homberg V, Lisnic V, Pugliatti M, Randall G, Saltuari L, Strilciuc S, Vester J, Muresanu D. European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke. Eur J Neurol. September 2021. doi:10.1111/ene.14936 · PMID 34152062
244. Journal / agency Szymkowicz E, Alnagger N, Seyfzadehdarabad F, Cardone P, Whyte J, Gosseries O. Coma and Disorders of Consciousness. 2023. doi:10.1007/978-3-031-50563-8_7
245. Journal / agency Masotta O, Trojano L, Loreto V, Moretta P, Estraneo A. Selegiline in Patients With Disorder of Consciousness: An Open Pilot Study. Can J Neurol Sci. November 2018. doi:10.1017/cjn.2018.315 · PMID 30430963
246. Journal / agency Selegiline transdermal (Emsam) - Somerset Pharmaceuticals. 5 November 2023
247. Journal / agency Selegiline orally disintegrating tablet (Efupi; FPF 1100 NW) - FP Pharmaceutical. 3 June 2016
248. Journal / agency Zeller EA, Barsky J. In vivo inhibition of liver and brain monoamine oxidase by 1-Isonicotinyl-2-isopropyl hydrazine. Proc Soc Exp Biol Med. November 1952. doi:10.3181/00379727-81-19910 · PMID 13027339
249. Other Sanofi Extends Holding in Chinoin. September 19, 1993
250. Journal / agency Knoll J, Ecseri Z, Kelemen K, Nievel J, Knoll B. Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer. Archives Internationales de Pharmacodynamie et de Therapie. May 1965. PMID 4378644
251. Journal / agency Bryant JM, Torosdag S, Schvartz N, Fletcher L, Fertig H, Schwartz MS, Quan RB. Antihypertensive properties of pargyline hydrochloride. New non-hydrazine monoamine oxidase inhibitor compared with sulphonamide diuretics. JAMA. October 1961. doi:10.1001/jama.1961.73040430005010 · PMID 13874134
252. Journal / agency Magyar K, Vizi ES, Ecseri Z, Knoll J. Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250). Acta Physiologica Academiae Scientiarum Hungaricae. 1967. PMID 5595908
253. Journal / agency Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. July 1968. doi:10.1016/0006-2952(68)90066-x · PMID 5659776
254. Journal / agency Knoll J, Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv Biochem Psychopharmacol. 1972. PMID 5066229
255. Journal / agency Knoll J, Vizi ES, Somogyi G. Phenylisopropylmethylpropynylamine (E-250), a Monoaminooxidase Inhibitor Antagonising Effects of Tyramine. Arzneimittel-Forschung. 1968
256. Other Varga E. III Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. 1965
257. Journal / agency Varga E, Tringer L. Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250"). Acta Med Acad Sci Hung. 1967. PMID 6056555
258. Other Tringer L, Haits G, Varga E. V. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia. 1971
259. Journal / agency Mann J, Gershon S. L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression. Life Sci. March 1980. doi:10.1016/0024-3205(80)90350-1 · PMID 6768943
260. Journal / agency Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. Journal of Neural Transmission. 1975. doi:10.1007/BF01253131 · PMID 1172524
261. Journal / agency Knoll J. The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence. Mech Ageing Dev. May 1985. doi:10.1016/0047-6374(85)90001-6 · PMID 3927074
262. Journal / agency Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm. 1985. doi:10.1007/BF01245973 · PMID 3935752
263. Journal / agency Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl. Mech Ageing Dev. December 1988. doi:10.1016/0047-6374(88)90128-5 · PMID 3147347
264. Other Cromie WJ. Bodkin is Patching up Depression. November 7, 2002
265. Other Bishop K. 'Smart Drugs': Elixir or Snake Oil?. 10 June 1992
266. Journal / agency Reynolds GP, Elsworth JD, Blau K, Sandler M, Lees AJ, Stern GM. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol. December 1978. doi:10.1111/j.1365-2125.1978.tb00883.x · PMID 728327 · PMC1429688
267. Journal / agency Dezsi L, Vecsei L. Monoamine Oxidase B Inhibitors in Parkinson's Disease. CNS Neurol Disord Drug Targets. 2017. doi:10.2174/1871527316666170124165222 · PMID 28124620
268. Journal / agency Knoll J. The Brain and Its Self: A Neurochemical Concept of the Innate and Acquired Drives. 2005. doi:10.1007/3-540-27434-0_4
269. Journal / agency Knoll J, Miklya I. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch Int Pharmacodyn Ther. 1994. PMID 7893186
270. Journal / agency Knoll J, Miklya I, Knoll B, Markó R, Kelemen K. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons. Life Sci. 1996. doi:10.1016/0024-3205(96)00014-8 · PMID 8602114
271. Journal / agency Knoll J, Knoll B, Török Z, Timár J, Yasar S. The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant. Arch Int Pharmacodyn Ther. 1992. PMID 1356324
272. Journal / agency Knoll J, Yoneda F, Knoll B, Ohde H, Miklya I. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Br J Pharmacol. December 1999. doi:10.1038/sj.bjp.0702995 · PMID 10588928 · PMC1571822
273. Journal / agency Knoll B, Timar J, Knoll J. Amphetamine-derived potent psychostimulants devoid of biogenic amine releasing properties. Pharmacological Research Communications. 1988. doi:10.1016/S0031-6989(88)80670-2
274. Journal / agency Frampton JE, Plosker GL. Selegiline transdermal system: in the treatment of major depressive disorder. Drugs. 2007. doi:10.2165/00003495-200767020-00006 · PMID 17284087
275. Other Duffy M. Patch Raises New Hope For Beating Depression. 3 December 2002
276. Journal / agency Cascade EF, Kalali AH, Preskorn SH. Emsam: the first year. Psychiatry. June 2007. PMID 20711332 · PMC2921248
277. Journal / agency Harsing LG, Knoll J, Miklya I. Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum. Int J Mol Sci. August 2022. doi:10.3390/ijms23158543 · PMID 35955676 · PMC9369307
278. Other Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 1990
279. Other Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 1999
280. Other Schweizerischer Apotheker-Verein. Index Nominum 2000: International Drug Directory. 2000
281. Other Drug Treatments for Parkinson's
282. Other Acosta WR. Pharmacology for Health Professionals. 2020
283. Journal / agency Knoll J, Zelena D, Timar J, Baghy K, Mervai Z, Miklya I. Synthetic enhancer compounds, besides acting on biogenic amine system, influence the glutamate transmission and stress response. Behav Brain Res. January 2020. doi:10.1016/j.bbr.2019.112290 · PMID 31610214
284. Other Feinberg S. EMSAM: A User-Friendly MAOI?. 1 November 2006
285. Journal / agency Dorsey ER, Thompson JP, Dayoub EJ, George B, Saubermann LA, Holloway RG. Selegiline shortage: Causes and costs of a generic drug shortage. Neurology. July 2009. doi:10.1212/WNL.0b013e3181ae7b04 · PMID 19620609 · PMC2715573
286. Other Hurwitz G. Out of the dark. 2019
287. Other Lidsky T, Schneider J. Brain Candy: Boost Your Brain Power with Vitamins, Supplements, Drugs, and Other Substance. 2010
288. Other Miklya I. Towards New Therapies for Parkinson's Disease. 2011
289. Other Saunders N, Heron L. E for Ecstasy. 1993
290. Other Saunders N. Test results of 30 samples of Ecstasy bought in British clubs between 11/94 and 7/95
291. Journal / agency Docherty JR. Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Br J Pharmacol. June 2008. doi:10.1038/bjp.2008.124 · PMID 18500382 · PMC2439527
292. Journal / agency Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present--a pharmacological and clinical perspective. J Psychopharmacol. June 2013. doi:10.1177/0269881113482532 · PMID 23539642 · PMC3666194
293. Journal / agency Barkholtz HM, Hadzima R, Miles A. Pharmacology of R-(-)-Methamphetamine in Humans: A Systematic Review of the Literature. ACS Pharmacol Transl Sci. July 2023. doi:10.1021/acsptsci.3c00019 · PMID 37470013 · PMC10353062
294. Journal / agency Smith RC, Davis JM. Comparative effects of d-amphetamine, l-amphetamine, and methylphenidate on mood in man. Psychopharmacology (Berl). June 1977. doi:10.1007/BF00426687 · PMID 407607
295. Journal / agency Zhou SF, Liu JP, Lai XS. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem. 2009. doi:10.2174/092986709788681985 · PMID 19601803

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.